

NATIONAL TOXICOLOGY PROGRAM  
Technical Report Series  
No. 217



**CARCINOGENESIS BIOASSAY  
OF  
DI(2-ETHYLHEXYL)PHTHALATE  
(CAS NO. 117-81-7)  
IN F344 RATS AND B6C3F<sub>1</sub> MICE  
(FEED STUDY)**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
National Institutes of Health

### **NATIONAL TOXICOLOGY PROGRAM**

The National Toxicology Program (NTP), established in 1978, develops and evaluates scientific information about potentially toxic and hazardous chemicals. This knowledge can be used for protecting the health of the American people and for the primary prevention of chemically induced disease. By bringing together the relevant programs, staff, and resources from the U.S. Public Health Service, DHHS, the National Toxicology Program has centralized and strengthened activities relating to toxicology research, testing and test development/validation efforts, and the dissemination of toxicological information to the public and scientific communities and to the research and regulatory agencies.

The NTP is comprised of four charter DHHS agencies: the National Cancer Institute, National Institutes of Health; the National Institute of Environmental Health Sciences, National Institutes of Health; the National Center for Toxicological Research, Food and Drug Administration; and the National Institute for Occupational Safety and Health, Centers for Disease Control. In June 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS.

**NTP Technical Report**  
**on the**  
**CARCINOGENESIS BIOASSAY**  
**of**  
**DI(2-ETHYLHEXYL)PHTHALATE**  
**(CAS No. 117-81-7)**  
**IN F344 RATS AND B6C3F<sub>1</sub> MICE**  
**(FEED STUDY)**



**NATIONAL TOXICOLOGY PROGRAM**  
**Research Triangle Park**  
**Box 12233**  
**North Carolina 27709**  
**and**  
**Bethesda, Maryland 20205**

**March 1982**

**NTP-80-37**  
**NIH Publication No. 82-1773**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES**  
**Public Health Service**  
**National Institutes of Health**

## NOTE TO THE READER

This is one in a series of experiments designed to determine whether selected chemicals produce cancer in animals. Chemicals selected for testing in the NTP carcinogenesis bioassay program are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection per se is not an indicator of a chemical's carcinogenic potential. Negative results, in which the test animals do not have a greater incidence of cancer than control animals, do not necessarily mean that a test chemical is not a carcinogen, inasmuch as the experiments are conducted under a limited set of conditions. Positive results demonstrate that a test chemical is carcinogenic for animals under the conditions of the test and indicate that exposure to the chemical is a potential hazard to humans. The determination of the risk to humans from chemicals found to be carcinogenic to animals requires a wider analysis which extends beyond the purview of this study.

This study was initiated by the National Cancer Institute's Carcinogenesis Testing Program, now part of the National Institute of Environmental Health Sciences, National Toxicology Program.

These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfield, VA 22161 (703-487-4650).

Comments and questions about the National Toxicology Program Technical Reports on Carcinogenesis Bioassays should be directed to the National Toxicology Program, located at Room A-306, Landow Building, Bethesda, MD 20205 (301-496-1152) or at Research Triangle Park, NC 27709 (919-541-3991).

Although every effort is made to prepare the Technical Reports as accurately as possible, mistakes may occur. Readers are requested to communicate any mistakes to the Deputy Director, NTP (P.O. Box 12233, Research Triangle Park, NC 27709), so that corrective action may be taken. Further, anyone who is aware of related ongoing or published studies not mentioned in this report is encouraged to make this information known to the NTP.

TABLE OF CONTENTS

	<u>Page</u>
Contributors . . . . .	vii
Reviewers . . . . .	ix
Abstract . . . . .	xi
Summary of Peer Review Comments . . . . .	xiii
I. Introduction . . . . .	1
II. Materials and Methods . . . . .	7
A. Chemical . . . . .	7
B. Dietary Preparation . . . . .	7
C. Animals . . . . .	7
D. Animal Maintenance . . . . .	9
E. Single-Dose, Acute and 14-Day Repeated-Dose Studies . .	9
F. Subchronic Studies . . . . .	12
G. Chronic Studies . . . . .	15
H. Clinical Examinations and Pathology . . . . .	15
I. Data Recording and Statistical Analyses . . . . .	15
III. Results - Rats . . . . .	19
A. Body Weights, Food Consumption, and Clinical Signs (Rats) . . . . .	19
B. Survival (Rats) . . . . .	19
C. Pathology (Rats) . . . . .	19
D. Statistical Analyses of Results (Rats) . . . . .	25
IV. Results - Mice . . . . .	37
A. Body Weights, Food Consumption, and Clinical Signs (Mice) . . . . .	37
B. Survival (Mice) . . . . .	37
C. Pathology (Mice) . . . . .	42
D. Statistical Analyses of Results (Mice) . . . . .	43
V. Discussion . . . . .	53
VI. Conclusion . . . . .	59
VII. Bibliography . . . . .	61

TABLES

Table 1	LD <sub>50</sub> Values for Rats and Mice Administered Di(2-ethylhexyl)phthalate . . . . .	3
Table 2	Effects of Di(2-ethylhexyl)phthalate Administered to Rats and Mice . . . . .	4

	<u>Page</u>	
Table 3	Sources and Descriptions of Materials Used for Animal Maintenance . . . . .	8
Table 4	Dosage, Survival, and Mean Body Weights of Rats Fed Diets Containing Di(2-ethylhexyl)phthalate for 14 Days . . . . .	10
Table 5	Dosage, Survival, and Mean Body Weights of Mice Fed Diets Containing Di(2-ethylhexyl)phthalate for 14 Days . . . . .	11
Table 6	Dosage, Survival, and Mean Body Weights of Rats Fed Diets Containing Di(2-ethylhexyl)phthalate for 13 Weeks . . . . .	13
Table 7	Dosage, Survival, and Mean Body Weights of Mice Fed Diets Containing Di(2-ethylhexyl)phthalate for 13 Weeks . . . . .	14
Table 8	Numbers of Animals, Dosage, and Weeks on Test for Rats and Mice on Chronic Feeding Studies of Di(2-ethylhexyl)phthalate . . . . .	16
Table 9	Feed and Compound Consumption in Male F344 Rats Receiving Di(2-ethylhexyl)phthalate . . . . .	21
Table 10	Feed and Compound Consumption in Female F344 Rats Receiving Di(2-ethylhexyl)phthalate . . . . .	22
Table 11	Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	28
Table 12	Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	32
Table 13	Feed and Compound Consumption in Male B6C3F1 Mice Receiving Di(2-ethylhexyl)phthalate . . . . .	39
Table 14	Feed and Compound Consumption in Female B6C3F1 Mice Receiving Di(2-ethylhexyl)phthalate . . . . .	40
Table 15	Analyses of the Incidence of Primary Tumors in Male Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	47

	<u>Page</u>	
Table 16	Analyses of the Incidence of Primary Tumors in Female Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	50
Table 17	Comparison of Target Organs Affected in Chronic Bioassays of Some Compounds Structurally Related to Di(2-ethylhexyl)phthalate . . . . .	57

FIGURES

Figure 1	Growth Curves for Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	20
Figure 2	Survival Curves for Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	23
Figure 3	Growth Curves for Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	38
Figure 4	Survival Curves for Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	41
Figure 5	Life Table for Male Mice Fed Diets Containing Di(2-ethylhexyl)phthalate: Liver Tumors . . . . .	45
Figure 6	Life Table for Female Mice Fed Diets Containing Di(2-ethylhexyl)phthalate: Liver Tumors . . . . .	46
Figure 7	Infrared Absorption Spectrum of Di(2-ethylhexyl) phthalate . . . . .	118
Figure 8	Nuclear Magnetic Resonance Spectrum of Di(2-ethylhexyl)phthalate . . . . .	119

APPENDIXES

Appendix A	Summary of the Incidence of Neoplasms in Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	67
Table A1	Summary of the Incidence of Neoplasms in Male Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	69
Table A2	Summary of the Incidence of Neoplasms in Female Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	73

	<u>Page</u>	
Appendix B	Summary of the Incidence of Neoplasms in Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	77
Table B1	Summary of the Incidence of Neoplasms in Male Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	79
Table B2	Summary of the Incidence of Neoplasms in Female Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	83
Appendix C	Summary of the Incidence of Nonneoplastic Lesions in Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	87
Table C1	Summary of the Incidence of Nonneoplastic Lesions in Male Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	89
Table C2	Summary of the Incidence of Nonneoplastic Lesions in Female Rats Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	95
Appendix D	Summary of the Incidence of Nonneoplastic Lesions in Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	101
Table D1	Summary of the Incidence of Nonneoplastic Lesions in Male Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	103
Table D2	Summary of the Incidence of Nonneoplastic Lesions in Female Mice Fed Diets Containing Di(2-ethylhexyl)phthalate . . . . .	108
Appendix E	Analysis of Di(2-ethylhexyl)phthalate -- Midwest Research Institute . . . . .	113
Appendix F	Stability Analysis of Di(2-ethylhexyl)phthalate -- Midwest Research Institute . . . . .	121
Appendix G	Analysis of Formulated Diets for Concentrations of Di(2-ethylhexyl)phthalate . . . . .	125



## CONTRIBUTORS

The bioassay of di(2-ethylhexyl)phthalate was conducted between March 1977 and June 1979 at EG&G Mason Research Institute, Worcester, Massachusetts, under a subcontract to Tracor Jitco, Inc., the prime contractor for the NCI Carcinogenesis Testing Program.

The bioassay was conducted under the supervision of Drs. H. Lilja (1) and E. Massaro (1,2), principal investigators. The program manager was Ms. R. Monson (1). Ms. A. Good (1) supervised the technicians in charge of animal care, and Ms. E. Zepp (1) supervised the preparation of the feed mixtures and collected samples of the diets for analysis. Ms. D. Bouthot (1) kept all daily records of the test. Dr. D. S. Wyand (1), pathologist, directed the necropsies and performed the histopathologic evaluations. The pathology report and selected slides were evaluated by the NCI Pathology Working Group as described in Ward et al. (1978). The diagnoses represent a consensus of contracting pathologists and the NCI Pathology Working Group with final approval by the NCI Pathology Working Group.

Animal pathology tables and survival tables were compiled at EG&G Mason Research Institute, Rockville, Maryland (3). The statistical analyses were performed by Dr. J. R. Joiner (4) and Ms. S. Vatsan (4), using methods selected for the bioassay program by Dr. J. J. Gart (5). Chemicals used in this bioassay were analyzed at Midwest Research Institute (6), and dosed feed mixtures were analyzed by Dr. M. Hagopian (1).

This report was prepared at Tracor Jitco (4) and reviewed by NTP. Those responsible for the report at Tracor Jitco were Dr. Cipriano Cueto, Director of the Bioassay Program; Dr. S. S. Olin, Associate Director; Dr. M. A. Stedham, pathologist; Dr. W. D. Theriault, reports manager; Dr. A. C. Jacobs, bioscience writer; and Ms. M. Glasser, technical editor.

The following scientists at NTP (7) were responsible for evaluating the bioassay experiment, interpreting the results, and reporting the findings: Dr. J. Fielding Douglas (Chemical Manager), Dr. Charles K. Grieshaber, Dr. Larry Hart, Dr. William V. Hartwell, Dr. Joseph Haseman, Dr. James Huff, Dr. William Kluwe, Dr. Mary Kornreich, Dr. Ernest E. McConnell, Dr. John A. Moore, Dr. Sherman F. Stinson, Dr. R. Tennant, and Dr. Jerrold M. Ward.

- 
- (1) EG&G Mason Research Institute, 57 Union Street, Worcester, Massachusetts 01608.
  - (2) Now with Pennsylvania State University, 226 Fenske Laboratory, University Park, Pennsylvania 16802.
  - (3) EG&G Mason Research Institute, 1530 East Jefferson Street, Rockville, Maryland 20852.
  - (4) Tracor Jitco, Inc., 1776 East Jefferson Street, Rockville, Maryland 20852.

- (5) Mathematical Statistics and Applied Mathematics Section, Biometry Branch, Field Studies and Statistics, Division of Cancer Cause and Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20205.
- (6) Midwest Research Institute, 425 Volker Boulevard, Kansas City, Missouri 64110.
- (7) Carcinogenesis Testing Program, National Institutes of Health, Bethesda, Maryland 20205; National Toxicology Program, Research Triangle Park, Box 12233, North Carolina 27709.

## REVIEWERS

On October 15, 1980, this carcinogenesis bioassay report on di(2-ethylhexyl)phthalate underwent peer review and was approved by the National Toxicology Program Board of Scientific Counselor's Technical Report Review Subcommittee and associated Panel of Experts at an open meeting held in Conference Room 6, Building 31C, National Institutes of Health, Bethesda, Maryland.

### National Toxicology Program Board of Scientific Counselors' Technical Report Review Subcommittee

Margaret Hitchcock, Ph.D. (Chairperson)  
Pharmacology/Toxicology  
John B. Pierce Foundation Laboratory  
New Haven, Connecticut

Curtis Harper, Ph.D.  
Associate Professor of  
Pharmacology  
University of North Carolina  
Chapel Hill, North Carolina

Alice Whittemore, Ph.D. \*  
Biostatistics  
Stanford University School of  
Medicine  
Palo Alto, California

Thomas Shepard, M.D.  
University of Washington  
School of Medicine  
Seattle, Washington

### Subcommittee Panel of Experts

Svend Nielsen, D.V.M., Ph.D.  
(Primary Reviewer)  
Professor of Pathology  
The University of Connecticut  
Storrs, Connecticut

Sheldon Murphy, Ph.D.  
University of Texas Medical  
School  
Houston, Texas

Norman Breslow, Ph.D.  
(Secondary Reviewer)  
Biostatistics  
University of Washington  
Seattle, Washington

Bernard Schwetz, Ph.D.  
Toxicology Research Laboratory  
Dow Chemical U.S.A.  
Midland, Michigan

Joseph Highland, Ph.D.\*  
Toxicology  
Environmental Defense Fund  
Washington, D.C.

Roy Shore, Ph.D.  
Statistics  
New York University Medical  
Center  
New York, New York

---

\*Unable to attend October 15, 1980 meeting

Charles Irving, Ph.D.\*  
Veterans Administration Hospital  
Cancer Research Laboratory  
Memphis, Tennessee

James Swenberg, Ph.D.  
Chief of Pathology  
Chemical Industry Institute of  
Toxicology  
Research Triangle Park,  
North Carolina

Frank Mirer, Ph.D.  
United Auto Workers  
International Union  
Detroit, Michigan

Gary Williams, M.D.\*  
Chief of Experimental Pathology  
American Health Foundation  
Valhalla, New York

## ABSTRACT

A bioassay of di(2-ethylhexyl)phthalate, the most commonly used plasticizer for polyvinylchloride polymers, for possible carcinogenicity was conducted by feeding diets containing 6,000 or 12,000 ppm of the test chemical to groups of 50 male and 50 female F344 rats and 3,000 or 6,000 ppm to groups of 50 male and 50 female B6C3F1 mice for 103 weeks. Controls consisted of 50 untreated rats and 50 untreated mice of either sex.

Mean body weights of dosed male rats (high- and low-dose), high-dose female rats, and dosed female mice (high- and low-dose) were marginally-to-moderately lower than those of the corresponding controls at the end of the chronic study, reflecting a decrease in body weight gain. Food consumption was reduced slightly in rats of either sex, whereas there was no apparent difference among the mouse groups.

Female rats and male and female mice administered di(2-ethylhexyl)phthalate had significantly higher incidences of hepatocellular carcinomas than those observed in the controls (rats -- males: 1/50, 2%; 1/49, 2%; 5/49, 10%; females -- 0/50, 0%; 2/49, 4%; 8/50, 16%,  $P=0.003$ ; mice -- males: 9/50, 18%; 14/48, 29%; 19/50, 38%,  $P=0.022$ ; females: 0/50, 0%; 7/50, 14%;  $P=0.006$ , 17/50, 34%,  $P < 0.001$ ). Further, a statistically significant positive trend for hepatocellular carcinomas occurred in female rats ( $P=0.002$ ) and in male ( $P=0.018$ ) and female ( $P < 0.001$ ) mice.

In addition, di(2-ethylhexyl)phthalate caused a statistically significant increased incidence of male rats with either hepatocellular carcinomas or neoplastic nodules (3/50, 6%; 6/49, 12%; 12/49, 24%;  $P=0.010$ ).

Degeneration of the seminiferous tubules was observed in the high-dose male rats (1/49, 2%; 2/44, 5%; 43/48, 90%) and in the high-dose male mice (1/49, 2%; 2/48, 4%; 7/49, 14%). Hypertrophy of cells in the anterior pituitary was also found at increased incidences in the high-dose male rats (1/46, 2%; 0/43, 0%; 22/49, 45%).

Under the conditions of this bioassay, di(2-ethylhexyl)phthalate was carcinogenic for F344 rats and B6C3F1 mice, causing increased incidences of female rats and male and female mice with hepatocellular carcinomas, and inducing an increased incidence of male rats with either hepatocellular carcinomas or neoplastic nodules.



SUMMARY OF PEER REVIEW COMMENTS ON THE BIOASSAY OF  
DI(2-ETHYLHEXYL)PHTHALATE

Dr. Nielsen, as the primary reviewer for the report on the bioassay of di(2-ethylhexyl)phthalate (DEHP), agreed with the conclusion that, under the conditions of the bioassay, DEHP was carcinogenic for F344 rats and B6C3F1 mice of either sex, causing increased incidence of hepatocellular carcinomas. He also noted that clear cell cytoplasmic changes of the liver occurred in multiple foci more frequently in low- and high-dose male rats than in controls.

As a secondary reviewer, Dr. Breslow agreed with the conclusion of the report. He pointed out that 21 of 57 hepatocellular carcinomas in dosed mice (both sexes) gave rise to pulmonary metastases, while there were no metastases in control mice or dosed rats. Tubular degeneration and atrophy of the testes was noted in 90% of high-dose male rats, against 2% and 5% of the control and low-dose animals. The high-dose male also had an elevated incidence of hypertrophy of the pituitary but decreased rates of pituitary carcinomas/adenomas, thyroid carcinomas/adenomas, and testicular interstitial-cell tumors compared with controls. The incidence of testicular or tubular degeneration in high-dose male mice (14%) was also elevated in comparison with the other groups. Possible shortcomings included the fact that there was unexplained early mortality in the low-dose female mice, leaving only 50% for terminal kill, and probably reducing the numbers of tumors appearing at necropsy.

As another secondary reviewer, Dr. Hitchcock also agreed with the conclusions of the report. She pointed out that statistically significant negative trends were observed in male rats for the incidence of carcinomas/adenomas of the pituitary, C-cell carcinomas/adenomas of the thyroid, and interstitial-cell tumors of the testes. She commented on the failure of the study to detect hepatomegaly, even though others have demonstrated this effect in subacute studies at concentrations below the lowest dose used in this study. She emphasized that hepatomegaly is an important toxicologic effect and may be an early indication for the development of hepatic lesions.

Dr. John Thomas (not a member of peer review panel) stated that these were the first reported positive studies with DEHP. He questioned why the F344 rat was used in view of the high spontaneous incidence of interstitial-cell tumors, approaching 100% at 24 months of age. Dr. Thomas also emphasized the mortality in control animals of about 33% in mice and 40% in male rats. Finally, he stated that the reviewers should address the significance of hepatocellular carcinomas and neoplastic nodules.


Dr. Swenberg initiated a discussion about combining hepatocellular carcinomas and neoplastic nodules for making a determination of carcinogenicity in male rats. Dr. Breslow raised the same question on combining hepatocellular carcinomas and adenomas in mice. Dr. Ward stated that the bioassay program for the last several years combined carcinomas and nodules or adenomas. He emphasized that neoplastic nodules and adenomas are tumors

which ordinarily progress. Dr. Swenberg contended that, since one cannot predict how many of the nodules progress to malignancy, one should do the statistical analyses for each type of liver lesion. Dr. David Rall (Director, NTP) and Dr. Norton Nelson (NTP Board Chairman) said that there were two separate issues: the description and analysis of the experimental findings, and the biological significance of these DEHP-induced tumors. A distinction should be made in the report. The NTP diagnoses these liver tumors as adenomas, as neoplastic nodules, or as carcinomas; the incidences of these tumors, as compared among dosed and control groups, are analyzed both separately and in combination. Dr. Nelson and Dr. Rall indicated that this is scientifically sound, and that the NTP would continue this practice. The Peer Review Panel in general seemed to agree that this was appropriate.

Dr. Nielsen moved that the report on the bioassay of di(2-ethylhexyl) phthalate be accepted after minor changes. Dr. Breslow added an amendment to the motion that the summary should distinguish statistically between hepatocellular adenomas and neoplastic nodules and carcinomas, identifying each specific type of neoplasm and calculating the statistical significance of each type.



## I. INTRODUCTION



### DI(2-ETHYLHEXYL) PHTHALATE

Di(2-ethylhexyl)phthalate (CAS No. 117-81-7) is the most commonly used plasticizer added to polymers such as polyvinylchloride for flexibility (Autian, 1973; and Tanaka et al., 1975). This phthalate ester is also used in nitrocellulose lacquers, cellulose acetate-butyrate, ethyl cellulose, natural and synthetic rubbers (W.R. Grace and Co., 1976) and as a pump fluid for oil diffusion pumps (Kirk-Othmer, 1970). Di(2-ethylhexyl)phthalate is present in vinyl tubing used for delivery of blood and intravenous fluids, and for milk processing (W. R. Grace and Co., 1976) and was approved by the U.S. Food and Drug Administration for use in polymers used in food contact articles (CFR, 1976). Three hundred and eighty-nine million pounds of di(2-ethylhexyl)phthalate were produced in the United States in 1977 (USITC, 1978). The recommended 8-hour time-weighted average for exposure of workers to di(2-ethylhexyl)phthalate in air is 5 mg/m<sup>3</sup> (Fed. Reg., 1974).

Although di(2-ethylhexyl)phthalate is insoluble in water, this viscous liquid is soluble in materials containing lipoproteins (Jaeger and Rubin, 1972; Gesler, 1973; and Thomas et al., 1978) and is found in concentrations as great as 66 mg/liter in blood that has been stored in vinyl bags and transferred through vinyl tubings (Baker, 1978). Concentrations of di(2-ethylhexyl)phthalate may reach 250 mg/liter in bagged plasma (Jacobson et al., 1974). Di(2-ethylhexyl)phthalate has been isolated from tissues of patients transfused with blood or blood products stored in flexible polyvinyl chloride containers, and was found in neonatal tissues after umbilical catheterization (Jaeger and Rubin, 1972; Hillman et al., 1975). It has been

estimated that a multi-transfused pediatric patient being treated for aplastic anemia, leukemia, or hemophilia might receive as much as 1,500 mg di(2-ethylhexyl)phthalate per year (28 mg/kg) (Jacobson et al., 1977).

A number of studies have been carried out on the disposition, toxic effects, and metabolic fate of di(2-ethylhexyl)phthalate in experimental animals. The LD<sub>50</sub> values reported for rats and mice administered di(2-ethylhexyl)phthalate are presented in Table 1. For the most part, the reported oral and intraperitoneal LD<sub>50</sub> values exceed 30 g/kg. The LD<sub>50</sub> values after intravenous administration ranged from 1.0 to 4.2 g/kg.

Steady state concentrations of 120 and 80 ppm di(2-ethylhexyl)phthalate were observed in the liver and fat of rats fed diets containing 5,000 ppm di(2-ethylhexyl)phthalate for 14 days (Daniel and Bratt, 1974). When the ester was administered by gavage to rats, it was first metabolized to mono(2-ethylhexyl)phthalate, which then underwent  $\omega$  and  $\omega-1$  oxidation as in endogenous fatty acid metabolism (Albro et al., 1973). These authors identified four mono(2-ethylhexyl)phthalate derivatives and phthalic acid in rat urine. The four mono(2-ethylhexyl)phthalate derivatives were: 5-keto-2-ethylhexyl ester, 5-hydroxy-2-ethylhexyl ester, 5-carboxyl-2-ethylpentyl ester, and 2-carboxylmethylbutyl ester. Free phthalic acid comprised less than 3% of the urinary metabolites. Furthermore, no evidence of conjugation was detected. Daniel and Bratt (1974) confirmed these findings of Albro et al. (1973). Di(2-ethylhexyl)phthalate was also degraded to mono(2-ethylhexyl)phthalate by the contents of the small intestine of Sprague-Dawley rats (Rowland, 1974).

Hepatomegaly was observed in male F344 rats fed diets containing 5,000 ppm di(2-ethylhexyl)phthalate for 1 week or administered 2,000 mg/kg by gavage for 21 days (Table 2), and similar effects were seen in Wistar rats administered the metabolite mono(2-ethylhexyl)phthalate by gavage (Lake et al., 1975).

Carcinogenic effects were not reported in 2-year bioassays with Sherman or Wistar rats of either sex fed diets containing up to 5,000 ppm di(2-ethylhexyl)phthalate (Carpenter et al., 1953; Harris et al., 1956). The design and reporting of these studies, however, were insufficient by

Table 1. LD<sub>50</sub> Values for Rats and Mice Administered Di(2-ethylhexyl)phthalate

Species	Route of Administration	LD <sub>50</sub> (mg/kg)	Reference
Rat	Oral	26,000	Patty, 1967
Rat (Wistar, male)	Oral	greater than 34,000	Hodge, 1943
Rat (Wistar, male)	Oral	30,600	Shaffer et al., 1945
Rat	Intravenous (sonicated in rat serum)	2,080	Petersen et al., 1974
Rat	Intraperitoneal	49,000	Singh et al., 1972
Rat (Wistar, male)	Intraperitoneal	30,600	Shaffer et al., 1945
Mouse	Oral	49,000	Yamada, 1974
Mouse	Oral	26,000	Patty, 1967
Mouse	Intravenous	1,060	Petersen et al., 1974
Mouse	Intraperitoneal	4,200	Calley et al., 1966
Mouse (ICR, male)	Intraperitoneal	38,000	Lawrence et al., 1975

Table 2. Effects of Di(2-ethylhexyl)phthalate Administered to Rats and Mice

Species/Sex	Route of Administration	Dose/Duration	Effects Observed	Reference
Rat (Wistar, male)	Dosed Feed	900-1,900 mg/kg for 90 days (a)	Tubular atrophy and degeneration of the testes	Shaffer et al., 1945
Rat (F344, male)	Dosed Feed	5,000 ppm for 1 week	Hepatomegaly	Reddy et al., 1976
Rat (CD, male)	Dosed Feed	10,000 ppm for 17 weeks	Seminiferous tubular atrophy and cessation of spermatogenesis; increased kidney weight	Gray et al., 1977
Rat (Wistar, male)	Gavage	2,000 mg/kg/day for 21 days	Hepatomegaly	Lake et al., 1975
Rat (male)	Intravenous	Single dose 200 mg/kg (b)	Lung edema	Rubin and Chang, 1978
Mouse (Swiss-Webster male)	Dosed feed	20,000 ppm for 4 weeks	Hepatomegaly	Reddy et al., 1976
Mouse	Dosed feed	5g/kg/day for 3 months	Renal cysts and hepatocellular necrosis	Ota et al., 1974

(a) 1.5%-3.0% in feed

(b) Solubilized in rat plasma

present-day standards for assessing carcinogenic potential. The test substance was found to be fetotoxic in Wistar rats (Onda et al., 1976) and fetotoxic and teratogenic in ddY-SLC mice (Yagi et al., 1976).

Abnormal liver histopathology was observed in rhesus monkeys receiving repeated transfusions of plasma containing low concentrations of the chemical (Jacobson et al., 1977). Changes consisted of vacuolated Kupffer cells, foci of parenchymal necrosis, chronic inflammatory cell infiltrates, and prominence or hyperplasia of Kupffer cells. Total doses of di(2-ethylhexyl)phthalate ranged from 7 to 33 mg over the 1-year administration period. Detectable concentrations of di(2-ethylhexyl)phthalate were present in the liver as long as 5 months following cessation of the transfusions. Decreased sulfobromophthalein clearance was observed, accompanied by abnormal liver histopathology, indicating a hepatotoxic potential in monkeys.

Results of chromosome aberration tests in Chinese hamster cells were negative (Ishidate and Odashima, 1977; and Abe and Sasaki, 1977), but positive results were obtained in a dominant lethal test in ICR mice (Singh et al., 1974). Di(2-ethylhexyl)phthalate was not mutagenic in Salmonella typhimurium TA 1535, TA 1537, TA 1538, TA 98, and TA 100 -- both with and without metabolic activation (Simmon et al., 1977); however, mono(2-ethylhexyl)phthalate was mutagenic in E. Coli (Yagi et al., 1976).

Di(2-ethylhexyl)phthalate was tested by the Carcinogenesis Testing Program because of the large amount produced, occupational exposure, and the widespread exposure of the general population to products containing this substance.



## II. MATERIALS AND METHODS

### A. Chemical

Di(2-ethylhexyl)phthalate (CAS No. 117-81-7) was obtained from W.R. Grace and Company (Fords, NJ) in one batch (Lot No. GC-2-26-76). Results of analyses of di(2-ethylhexyl)phthalate at Midwest Research Institute, Kansas City, Missouri, were consistent with the structure (Appendix E). Results of thin-layer chromatography indicated one homogeneous spot, and those of vapor-phase chromatography indicated two minor impurities having a total area less than 0.5% of the major peak. Integration values for aromatic protons in the nuclear magnetic resonance spectrum were slightly high.

### B. Dietary Preparation

Test diets were prepared by mixing the chemical with an aliquot of powdered Wayne Lab Blox<sup>®</sup> animal feed (Table 3) and placing this mixture with the remainder of the feed in a Patterson-Kelly blender with an intensifier bar and mixing for 15 minutes. Test diets were sealed in labeled plastic bags and stored at 4°C for no longer than 14 days.

Sample diets formulated with 100,000 ppm di(2-ethylhexyl)phthalate were stored at -20°, 5°, 25°, or 45°C for 2 weeks. Di(2-ethylhexyl)phthalate was found to be stable at 45°C (Appendix F). The concentrations of the test substance in randomly selected batches of formulated diets were within +10% of the target concentrations (Appendix G).

### C. Animals

Four- to five-week old F344 rats and 5-week old B6C3F1 mice were obtained from the NCI Frederick Cancer Research Center (Frederick, MD), isolated for 9 days (mice) or 7 days (rats), examined for the presence of parasites or other diseases, and assigned to control or dosed groups so that average cage weights were approximately equal for all animals of the same sex and species.

Table 3. Sources and Descriptions of Materials Used for Animal Maintenance

---

Item	Description	Source
Animal Feed	Wayne <sup>®</sup> Lab Blox Meal	Allied Mills (Chicago, IL)
Feed Hoppers	Stainless steel, gang style	Scientific Cages, Inc. (Bryan, TX)
Cages	Polycarbonate	Lab Products, Inc. (Rochelle Park, NJ)
Filter Sheets	Disposable, nonwoven fiber	Lab Products, Inc. (Rochelle Park, NJ)
Bedding	Hardwood chips: Aspen bed	American Excelsior (Baltimore, MD.)
	Betta Chips <sup>®</sup>	Agway Corp. (Syracuse, NY)

---



#### D. Animal Maintenance

Rats and mice were housed five per cage in suspended polycarbonate cages equipped with disposable nonwoven fiber filter sheets (Table 3). Hardwood chip bedding and cages were changed twice weekly, and cage racks were changed every 2 weeks. Water, supplied by an Edstrom automatic watering system, and powdered Wayne Lab Blox<sup>®</sup> meal in stainless-steel, gang-style hoppers that were changed once per week were available ad libitum.

The temperature of animal rooms was 17<sup>o</sup>-31<sup>o</sup>C (average 23<sup>o</sup>C) and relative humidity was 10%-88%. Incoming air was filtered through Tri-Dek 15/40 denier Dacron filters, with 10 room air changes per hour. Fluorescent lighting was provided 12 hours per day.

Rats and mice were housed by species in rooms in which chronic feeding studies were being conducted on guar gum (CAS 9000-30-0), butyl benzyl phthalate (CAS 85-68-7), and di(2-ethylhexyl)adipate (CAS 103-23-1).

#### E. Single-Dose, Acute, and 14-Day Repeated-Dose Studies

Single-dose and 14-day repeated-dose feed studies using F344 rats and B6C3F1 mice were conducted to determine the concentrations of di(2-ethylhexyl)phthalate to be used in the subchronic studies.

In the acute toxicity test, groups of five males and five females of each species were treated once with various doses (0.8-20 g/kg, rats; 1.25-20 g/kg, mice) of the test substance in corn oil by gavage. All animals survived the 14-day observation period.

In the repeated-dose study, groups of five males and five females of each species were tested for 2 weeks with five concentrations of the test substance in feed, followed by 1 day of observation (control diet); similar groups were maintained as untreated controls (Tables 4 and 5). All surviving animals were killed on day 16.

Two of 5 male rats and 4/5 female rats fed 100,000 ppm di(2-ethylhexyl)phthalate died during the study. Weight gain (when compared with controls) was depressed by more than 25% in males receiving 25,000 ppm or more and

Table 4. Dosage, Survival, and Mean Body Weights of Rats Fed Diets Containing Di(2-ethylhexyl)phthalate for 14 Days

Dose (ppm)	Survival(a)	Mean Body Weights (grams)			Weight Change Relative to Controls (b) (Percent)
		Initial	Final	Gain	
<u>Male</u>					
0	5/5	122.8	168.4	45.0	
6,300	5/5	123.4	174.0	50.6	+12
12,500	5/5	123.4	175.6	52.2	+16
25,000	5/5	123.4	155.2	31.8	-29
50,000	5/5	123.4	126.2	2.8	-94
100,000	3/5	123.4	79.6	-43.8	-197
<u>Female</u>					
0	5/5	101.2	116.8	15.6	
6,300	5/5	101.0	133.4	32.4	+108
12,500	5/5	101.0	121.0	20.0	+28
25,000	5/5	101.0	117.6	16.6	+6
50,000	5/5	101.0	90.8	-10.2	-165
100,000	1/5	101.0	90.0	-11.0	-171

(a) Number surviving/number per group

(b) Weight Change Relative to Controls =

$$\frac{\text{Weight Gain (Dosed Group)} - \text{Weight Gain (Control Group)}}{\text{Weight Gain (Control Group)}} \times 100$$

Table 5. Dosage, Survival, and Mean Body Weights of Mice Fed Diets Containing Di(2-ethylhexyl)phthalate for 14 Days

Dose (ppm)	Survival (a)	Mean Body Weights (grams)			Weight Change Relative to Controls (b) (Percent)
		Initial	Final	Gain	
<u>Male</u>					
0	5/5	25.4	28.0	2.6	
6,300	5/5	25.4	26.2	0.8	-69
12,500	5/5	25.4	26.0	0.6	-77
25,000	5/5	25.4	23.0	-2.4	-192
50,000	4/5	25.4	20.0	-5.4	-308
100,000	0/5	25.4	19.8	-5.6	-315
<u>Female</u>					
0	5/5	18.6	19.4	0.8	
6,300	5/5	18.6	19.0	0.4	-50
12,500	5/5	18.6	19.8	1.2	+50
25,000	5/5	18.6	19.8	1.2	+50
50,000	1/5	18.6	14.7	-3.9	-588
100,000	0/5	18.6	14.0	-4.6	-675

(a) Number surviving/number per group

(b) Weight Change Relative to Controls =

$$\frac{\text{Weight Gain (Dosed Group)} - \text{Weight Gain (Control Group)}}{\text{Weight Gain (Control Group)}} \times 100$$

in females receiving 50,000 ppm or more. Males receiving 100,000 ppm and females receiving 50,000 or 100,000 ppm lost weight. Rats receiving 100,000 ppm maintained hunched positions and were lethargic.

One of five male mice receiving 50,000 ppm and all (5/5) males receiving 100,000 ppm died. Four of five female mice receiving 50,000 ppm and all (5/5) females receiving 100,000 ppm died. A dose-related decrease in mean body weight gain occurred in male mice. Male mice receiving 25,000 ppm or more and females receiving 50,000 ppm or more lost weight.

#### F. Subchronic Studies

Subchronic studies were conducted to determine the high and low doses to be used in the chronic studies. Diets containing 0, 1,600, 3,100, 6,300, 12,500, or 25,000 ppm di(2-ethylhexyl)phthalate were fed for 13 weeks to groups of male and female rats. Similar groups of male and female mice received diets containing 0, 800, 1,600, 3,100, 6,300, or 12,500 ppm (Tables 6 and 7). Clinical observations were made twice daily and animals were weighed weekly. At the end of the 91-day study, survivors were killed, necropsies were performed on all animals, and tissues were taken for histopathologic analysis (see Section H).

Rats: Five female controls died due to accidents. One male rat fed 6,300 ppm died. Depression of mean body weight gain of male and female rats fed 25,000 ppm was 29% and 53%, respectively, relative to controls. Testicular atrophy, not considered to be life threatening, was observed in all 10 male rats fed 25,000 ppm and was present, but less pronounced, in rats fed 12,500 ppm. No other compound-related histopathologic effects were observed. Doses selected for rats for the chronic study were 6,000 and 12,000 ppm di(2-ethylhexyl)phthalate in feed.

Mice: Six of the seven deaths in the males fed 12,500 ppm were accidental, and one female died in each of the control, 6,300- and 12,500-ppm groups. Two females died in the 3,100 ppm group. A mean body weight gain depression of 10% or more was observed in males fed 3,100, 6,300 or 12,500 ppm and in all groups of dosed females except for those fed 1,600 ppm. No

Table 6. Dosage, Survival, and Mean Body Weights of Rats Fed Diets Containing Di(2-ethylhexyl)phthalate for 13 Weeks

Dose (ppm)	Survival (a)	Mean Body Weight (grams)			Weight Change Relative to Controls (c) (%)
		Initial	Final	Change (b)	
<u>Male</u>					
0	10/10	79.9 ± 3.3	291.7 ± 15.5	+211.8 ± 16.5	
1,600	10/10	79.9 ± 4.2	325.9 ± 9.0	+246.0 ± 6.3	+16.1
3,100	10/10	79.6 ± 4.2	315.2 ± 6.4	+235.6 ± 3.6	+11.2
6,300	9/10	81.3 ± 4.3	290.8 ± 12.4	+209.5 ± 9.0	- 1.1
12,500	10/10	79.7 ± 3.2	271.5 ± 7.4	+191.8 ± 6.5	- 9.4
25,000	10/10	79.8 ± 3.1	231.2 ± 10.3	+151.4 ± 7.7	-28.5
<u>Female</u>					
0	5/10	74.8 ± 3.1	181.4 ± 7.1	+106.6 ± 8.2	
1,600	10/10	76.2 ± 5.4	197.5 ± 5.5	+121.3 ± 4.6	+13.8
3,100	10/10	76.2 ± 4.0	196.2 ± 3.7	+120.0 ± 5.1	+12.6
6,300	10/10	76.2 ± 2.7	192.1 ± 3.3	+115.9 ± 2.8	+ 8.7
12,500	10/10	76.2 ± 2.1	179.0 ± 4.7	+102.8 ± 3.7	- 3.6
25,000	10/10	76.2 ± 1.6	126.4 ± 3.6	+ 50.2 ± 3.4	-52.9

(a) Number surviving/number initially in the group. All calculations are based on those animals surviving to the end of the study.

(b) Mean weight change of the survivors of the group ± Standard error of the mean

(c) Weight change of the dosed survivors relative to the survivors of the controls =

$$\frac{\text{Weight Change (Dosed Group)} - \text{Weight Change (Control Group)}}{\text{Weight Gain (Control Group)}} \times 100$$

Table 7. Dosage, Survival, and Mean Body Weights of Mice Fed Diets Containing Di(2-ethylhexyl)phthalate for 13 Weeks

Dose (ppm)	Survival (a)	Mean Body Weight (grams)			Weight Change Relative to Controls (c) (%)
		Initial	Final	Change(b)	
<u>Male</u>					
0	10/10	20.0 ± 0.4	34.4 ± 1.0	+14.4 ± 1.1	
800	10/10	20.0 ± 0.4	33.9 ± 0.6	+13.9 ± 0.5	- 3.5
1,600	10/10	20.0 ± 0.4	34.4 ± 0.9	+14.4 ± 1.1	0.0
3,100	10/10	20.0 ± 0.5	32.8 ± 0.8	+12.8 ± 0.8	-11.1
6,300	10/10	20.0 ± 0.5	31.3 ± 0.5	+11.3 ± 0.4	-21.5
12,500	3/10	19.0 ± 0.6	29.4 ± 0.8	+10.4 ± 0.4	-27.8
<u>Female</u>					
0	9/10	16.7 ± 0.4	26.3 ± 0.5	+9.6 ± 0.3	
800	10/10	16.6 ± 0.3	24.5 ± 0.3	+7.9 ± 0.2	-17.7
1,600	10/10	16.6 ± 0.3	25.4 ± 0.5	+8.8 ± 0.4	- 8.3
3,100	8/10	16.8 ± 0.4	25.2 ± 0.8	+8.4 ± 0.7	-12.5
6,300	9/10	16.6 ± 0.4	23.7 ± 0.7	+7.1 ± 0.5	-26.0
12,500	9/10	16.6 ± 0.4	23.1 ± 0.5	+6.5 ± 0.4	-32.3

(a) Number surviving/number initially in the group. All calculations are based on those animals surviving to the end of the study.

(b) Mean weight change of the survivors of the group ± Standard error of the mean

(c) Weight change of the dosed survivors relative to the survivors of the controls =

$$\frac{\text{Weight Change (Dosed Group)} - \text{Weight Change (Control Group)}}{\text{Weight Gain (Control Group)}} \times 100$$

other compound-related effects were observed. Doses selected for mice for the chronic study were 3,000 and 6,000 ppm di(2-ethylhexyl)phthalate in feed.

#### G. Chronic Studies

The test groups, doses administered, and durations of the chronic studies are shown in Table 8.

#### H. Clinical Examinations and Pathology

Animals were inspected twice daily. Individual animal body weights were recorded monthly. Animals that were moribund and those that survived to the end of the study were killed using CO<sub>2</sub> inhalation and necropsied.

Gross and microscopic examinations were performed on major tissues, major organs, and all gross lesions from killed animals and from animals found dead. Tissues were preserved in 10% neutral buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The following tissues were examined microscopically: skin, lungs and bronchi, trachea, bone and bone marrow, spleen, lymph nodes, heart, salivary gland, liver, pancreas, stomach, small intestine, large intestine, kidneys, urinary bladder, pituitary, adrenal, thyroid, parathyroid, mammary gland, prostate and seminal vesicles or uterus, testis or ovary, brain, thymus, larynx, and esophagus.

Necropsies were performed on all animals found dead unless precluded in whole or in part by autolysis or cannibalization. Thus, the number of animals from which particular organs or tissues were examined microscopically varies and does not necessarily represent the number of animals that were placed on study in each group.

#### I. Data Recording and Statistical Analyses

Data on this experiment were recorded in the Carcinogenesis Bioassay Data System (Linhart et al., 1974). The data elements include descriptive information on the chemicals, animals, experimental design, clinical observations,

Table 8. Numbers of Animals, Dosage, and Weeks on Test for Rats and Mice on Chronic Feeding Studies of Di(2-ethylhexyl)phthalate

Test Group	Initial No. of Animals	Di(2-ethylhexyl)-phthalate (ppm)	Weeks on Study	
			Dosed	Observed
<u>Male Rats</u>				
Control	50	0	0	105
Low-Dose	50	6,000	103	2
High-Dose	50	12,000	103	1
<u>Female Rats</u>				
Control	50	0	0	105
Low-Dose	50	6,000	103	2
High-Dose	50	12,000	103	2
<u>Male Mice</u>				
Control	50	0	0	105
Low-Dose	50	3,000	103	2
High-Dose	50	6,000	103	1
<u>Female Mice</u>				
Control	50	0	0	105
Low-Dose	50	3,000	103	2
High-Dose	50	6,000	103	2



survival, body weight, and individual pathologic results, as recommended by the International Union Against Cancer (Berenblum, 1969).

Probabilities of survival were estimated by the product-limit procedure of Kaplan and Meier (1958) and are presented in this report in the form of graphs. Statistical analyses for a possible dose-related effect on survival used the method of Cox (1972) for testing two groups for equality and Tarone's (1975) extension of Cox's methods for testing for a dose-related trend. One-tailed P values have been reported for all tests except the departure from linearity test, which is reported only when its two-tailed P value is less than 0.05.

The incidence of neoplastic or nonneoplastic lesions has been given as the ratio of the number of animals bearing such lesions at a specific anatomic site (numerator) to the number of animals in which that site is examined (denominator). In most instances, the denominators included only those animals for which that site was examined histologically. However, when macroscopic examination was required to detect lesions prior to histologic sampling (e.g., skin or mammary tumors) or when lesions could have appeared at multiple sites (e.g., lymphomas), the denominators consist of the numbers of animals necropsied.

The purpose of the statistical analyses of tumor incidence is to determine whether animals receiving the test chemical developed a significantly higher proportion of tumors than did the control animals. As a part of these analyses, the one-tailed Fisher exact test (Cox, 1970) was used to compare the tumor incidence of a control group with that of a group of dosed animals at each level. When results for two dosed groups are compared simultaneously with those for a control group, a correction to ensure an overall significance level of 0.05 is made. The Bonferroni inequality criterion (Miller, 1966) requires that the P value for any comparison be less than or equal to 0.025. When this correction was used, it is discussed in the narrative section. It is not presented in the tables, where the Fisher exact P values are shown.

The Cochran-Armitage test for linear trend in proportions, with continuity correction (Armitage, 1971), was also used. Under the assumption of a linear trend, this test determines if the slope of the dose-response curve

is different from zero at the one-tailed 0.05 level of significance. Unless otherwise noted, the direction of the significant trend is a positive dose relationship. This method also provides a two-tailed test of departure from linear trend.

A time-adjusted analysis was also applied. In this analysis, deaths that occurred before the first tumor was observed were excluded by basing the statistical tests on animals that survived 52 weeks, unless a tumor was found at an anatomic site of interest before week 52. When such an early tumor was found, comparisons were based exclusively on animals that survived at least as long as the animal in which the first tumor was found. Once this reduced set of data was obtained, the standard procedures for the analyses of the incidence of tumors (Fisher exact tests, Cochran-Armitage Tests, etc.) were followed.

Life table methods were used to analyze the incidence of tumors. Curves of the proportions surviving without an observed tumor were computed as in Saffiotti et al. (1972). The week during which an animal died naturally or was killed was entered as the time point of tumor observation. The methods of Cox and of Tarone were used for the statistical tests of the groups. The statistical tests were one-tailed.

The approximate 95% confidence interval for the relative risk of each dosed group compared with its control was calculated from the exact interval on the odds ratio (Gart, 1971). The lower and upper limits of the confidence interval of the relative risk have been included in the tables of statistical analyses. The interpretation of the limits is that, in approximately 95% of a large number of identical experiments, the true ratio of the risk in a dosed group of animals to that in a control group would be within the interval calculated from the experiment.

When the lower limit of the confidence interval is greater than one, it can be inferred that a statistically significant result has occurred (P less than 0.025 one-tailed test when the control incidence is not zero, P less than 0.050 when the control incidence is zero).

When the lower limit is less than unity but the upper limit is greater than unity, the lower limit indicates the absence of a significant result while the upper limit indicates there is a theoretical possibility of the induction of tumors by the test chemical, which could not be detected under the conditions of this test.

### III. RESULTS - RATS

#### A. Body Weights, Food Consumption, and Clinical Signs (Rats)

A dose-related decrease in mean body weight gain was observed throughout the study for male rats (Figure 1). Body weight gain in female rats was also reduced by the high (12,000 ppm) dose of di(2-ethylhexyl)phthalate. Daily mean food consumptions were reduced slightly in the dosed groups relative to controls (Tables 9 and 10). The average daily feed consumption per rat was 86% and 85% that of controls for low-dose males and females, respectively, and 86% and 75% for high-dose males and females, respectively. Mean daily doses of di(2-ethylhexyl)phthalate (g per kg body weight) were 0.322 and 0.674 for low- and high-dose males, respectively, and 0.394 and 0.774 for low- and high-dose females, respectively. No other compound-related clinical signs of toxicity were reported.

#### B. Survival (Rats)



Estimates of the probabilities of survival of male and female rats administered di(2-ethylhexyl)phthalate in feed, together with those of the control group, are shown by the Kaplan and Meier curves in Figure 2. No significant trends in mortality were observed.

In male rats, 30/50 (60%) of the control, 28/50 (56%) of the low-dose, and 33/50 (66%) of the high-dose group lived to the end of the study at 104-105 weeks. In female rats, 36/50 (72%) of the control, 34/50 (68%) of the low-dose, and 38/50 (76%) of the high-dose group lived to the end of the study at 105 weeks.

A sufficient number of rats were at risk for the development of late appearing tumors.

#### C. Pathology (Rats)

Histopathologic findings on neoplasms in rats are summarized in Appendix A, Tables A1 and A2; findings on nonneoplastic lesions are summarized in Appendix C, Tables C1 and C2.



**Figure 1. Growth Curves for Rats Fed Diets Containing Di(2-ethylhexyl)phthalate**

Table 9. Feed and Compound Consumption in Male F344 Rats Receiving Di(2-ethylhexyl)phthalate


Week	Control			Low			High			
	Grams Feed/Day(a)	Body Weight (grams)	Dose/Day (c)	Grams Feed/Day(a)	Body Weight (grams)	Low Control (b)	Grams Feed/Day(a)	Body Weight (grams)	High Control (b)	Dose/Day (c)
Male										
4	29.7	223	0.770	26.6	207	0.9	25.6	197	0.9	1.558
8	24.4	275	0.492	21.0	256	0.9	19.4	245	0.8	0.952
12	23.7	326	0.374	18.3	293	0.8	18.4	281	0.8	0.787
16	24.6	357	0.369	19.6	318	0.8	20.1	305	0.8	0.793
20	21.1	359	0.334	18.1	326	0.9	18.1	311	0.9	0.700
25	14.1	370	0.207	11.9	344	0.8	12.1	330	0.9	0.442
28	21.9	387	0.297	17.1	346	0.8	18.6	332	0.8	0.671
33	19.6	371	0.341	20.0	352	1.0	17.7	335	0.9	0.635
36	19.6	406	0.292	17.9	367	0.9	18.4	351	0.9	0.630
40	23.6	419	0.303	18.9	373	0.8	19.1	354	0.8	0.649
44	21.7	426	0.291	18.4	380	0.8	18.9	363	0.9	0.623
48	23.0	433	0.302	19.6	389	0.9	20.4	361	0.9	0.679
52	22.9	436	0.305	19.9	391	0.9	20.1	373	0.9	0.648
56	20.1	433	0.280	18.1	389	0.9	19.7	377	1.0	0.628
60	24.1	433	0.313	20.1	386	0.8	17.6	368	0.7	0.573
64	24.6	426	0.260	16.1	373	0.7	15.1	360	0.6	0.505
68	22.4	430	0.290	18.9	390	0.8	14.9	369	0.7	0.483
72	23.7	440	0.256	17.0	398	0.7	20.6	380	0.9	0.650
78	26.4	443	0.349	23.4	403	0.9	22.6	384	0.9	0.705
80	19.0	450	0.237	16.0	405	0.8	16.1	385	0.8	0.503
84	19.0	444	0.300	20.0	400	1.1	18.0	364	0.9	0.593
88	13.0	448	0.183	12.3	402	0.9	13.1	379	1.0	0.416
92	20.4	438	0.286	19.1	401	0.9	18.9	372	0.9	0.608
96	21.9	426	0.315	20.7	395	0.9	22.6	373	1.0	0.726
100	19.6	421	0.308	19.1	373	1.0	20.4	358	1.0	0.685
Mean	21.8	401	0.322	18.7	362	0.9	18.7	344	0.9	0.674
SD (d)	3.5	56.9	0.110	3.0	49.5	0.1	2.9	45.9	0.1	0.217
CV (e)	16.1	14.2	34.2	16.0	13.7	11.1	15.5	13.3	11.1	32.2

(a) Grams of feed consumed per animal per day.  
 (b) Grams of feed per day for the dosed group divided by the same value for the controls.  
 (c) Grams of compound consumed per day per kg of body weight.  
 (d) Standard Deviation  
 (e) Coefficient of Variation (standard deviation/mean x 100).

Table 10. Feed and Compound Consumption in Female F344 Rats Receiving Di(2-ethylhexyl)phthalate

Week	Control			Low			High			
	Grams Feed/Day(a)	Body Weight (grams)	Dose/Day (c)	Grams Feed/Day(a)	Body Weight (grams)	Low Control (b)	Grams Feed/Day(a)	Body Weight (grams)	High Control (b)	Dose/Day (c)
4	26.6	152	0.961	23.9	149	0.9	21.0	143	0.8	1.762
8	22.0	181	0.575	16.9	176	0.8	14.3	168	0.6	1.020
12	16.4	199	0.462	14.9	193	0.9	13.0	185	0.8	0.843
16	21.3	209	0.477	16.1	203	0.8	13.6	191	0.6	0.853
20	20.1	220	0.453	16.1	214	0.8	12.6	199	0.6	0.758
24	12.1	222	0.321	11.6	216	1.0	8.7	200	0.7	0.523
28	20.4	232	0.448	16.9	226	0.8	13.6	209	0.7	0.779
33	19.0	240	0.447	17.0	228	0.9	13.3	208	0.7	0.766
36	18.0	241	0.343	12.6	220	0.7	12.9	215	0.7	0.718
40	20.9	249	0.302	12.3	244	0.6	13.1	219	0.6	0.720
44	20.4	256	0.429	18.0	252	0.9	14.9	223	0.7	0.799
48	21.1	262	0.412	17.7	258	0.8	14.9	228	0.7	0.782
52	19.9	272	0.383	16.9	264	0.8	14.6	233	0.7	0.750
56	18.4	279	0.350	16.0	274	0.9	13.6	236	0.7	0.690
60	20.1	286	0.370	17.0	276	0.8	14.9	236	0.7	0.755
64	18.1	292	0.281	13.1	281	0.7	12.4	239	0.7	0.624
68	19.9	304	0.331	16.1	293	0.8	9.7	246	0.5	0.474
72	20.9	312	0.308	15.6	303	0.7	15.7	257	0.8	0.734
76	23.7	322	0.404	21.0	312	0.9	19.4	261	0.8	0.893
80	16.6	328	0.273	14.3	314	0.9	13.9	261	0.8	0.637
84	20.0	336	0.348	18.1	313	0.9	17.0	264	0.8	0.773
88	12.6	337	0.214	11.6	325	0.9	10.9	269	0.9	0.484
92	17.1	345	0.321	17.7	331	1.0	15.1	264	0.9	0.688
96	16.7	340	0.342	18.9	331	1.1	18.9	278	1.1	0.814
100	16.3	338	0.300	16.0	320	1.0	16.1	271	1.0	0.715
Mean	19.1	270	0.394	16.2	261	0.9	14.3	228	0.8	0.774
SD (d)	3.1	55.2	0.142	2.8	52.2	0.1	2.8	34.7	0.1	0.239
CV (e)	16.2	20.4	36.0	17.3	20.0	11.1	19.6	15.2	12.5	30.9

(a) Grams of feed consumed per animal per day.  
 (b) Grams of feed per day for the dosed group divided by the same value for the controls.  
 (c) Grams of compound consumed per day per kg of body weight.  
 (d) Standard Deviation  
 (e) Coefficient of Variation (standard deviation/mean x 100).



**Figure 2. Survival Curves for Rats Fed Diets Containing Di(2-ethylhexyl)phthalate**

Neoplastic nodules of the liver were observed at increased incidences in low- (5/49, 10%) and high-dose (7/49, 14%) males compared with controls (2/50, 4%) and in high-dose (5/50, 10%) and low-dose (4/49, 8%) females compared with controls (0/50,0%). The combined incidences of neoplastic nodules and hepatocellular carcinoma were elevated in high-dose (12/49, 24%) males and in both low (6/49, 12%) and high-dose (13/50, 26%) females. Control males had a combined incidence of 3/50 (6%), while the incidence in control female rats was zero.

Neoplastic nodules were generally spherical and caused compression of adjacent liver plates. The hepatocytes were well differentiated, and the general architecture of hepatic cords remained intact. Nodules were comprised of eosinophilic, vacuolated, and basophilic cells; however, the predominant neoplastic hepatocyte had basophilic cytoplasm. Some of the smaller nodules were composed of clear and basophilic hepatocytes, suggesting that clear cell foci progressed to these nodules.

Hepatocellular carcinomas varied from well to poorly differentiated. Well-differentiated tumors had trabecular and solid patterns with sinusoidal ectasia. The majority of carcinomas were composed of hepatocytes with basophilic cytoplasm. A few tumors had poorly differentiated areas containing solid, papillary, and trabecular foci with considerably more pleomorphism. Sinusoidal ectasia was often extensive. Large hyperchromatic nuclei, numerous mitoses, hyaline droplets, and fatty vacuoles were seen. Invasive growth at the tumor margins was greater in poorly differentiated tumors. There were no metastatic hepatocellular carcinomas in either male or female rats.

Clear cell cytoplasmic change, usually multiple, occurred in the livers of both low-dose (10/49, 20%) and high-dose (11/49, 22%) male rats. The change was present in only 4/50 (8%) of male controls.

Bilateral tubular degeneration and atrophy of the testes were seen in 90% of high-dose males. This lesion was noted in only 2% of control rats. Microscopically, the seminiferous tubules were devoid of germinal epithelium and spermatocytes. Only Sertoli cells were seen on tubular basement membranes. Interstitial cells were somewhat prominent.



Hypertrophy of cells in the anterior pituitary occurred in 45% of high-dose male rats compared with 2% of controls. These cells had cytoplasmic enlargement with the nucleus pushed to one side of the cell. The cytoplasm had a ground glass appearance, and clear cytoplasmic vacuoles were found in some hypertrophied cells.

No other toxic or preneoplastic lesions were associated with compound administration. The remaining nonneoplastic lesions were those commonly found in aging rats of this strain and were not considered to be compound related.

Histopathologic examination indicated that, under the conditions of this bioassay, the administration of di(2-ethylhexyl)phthalate was associated with an increased incidence of liver tumors in F344 rats.

#### D. Statistical Analyses of Results (Rats)

Tables 11 and 12 contain the statistical analyses of those primary tumors that occurred in at least two animals of one group and with an incidence of at least 5% in one or more groups.

Hepatocellular carcinomas or neoplastic nodules of the liver in male rats were observed in a statistically significant positive relation. The Cochran-Armitage test for linear trend was statistically significant in the positive direction ( $P=0.007$ ). The Fisher exact test between the high-dose group and the control group was significant ( $P=0.01$ ). No significant incidence was observed in the low-dose group; however, these tumors occurred in increased incidences in the low-dose group compared with the control group. In female rats, hepatocellular carcinomas or neoplastic nodules were observed in increased incidence in the dosed groups compared with the control group, the incidences being 0/50 (0%) in the controls, 6/49 (12%) in the low-dose, and 13/50 (26%) in the high-dose groups. The Cochran-Armitage test for linear trend was statistically significant in the positive direction ( $P$  less than 0.001) and the Fisher exact test between the control group and either of the dosed groups was significant ( $P=0.012$  in the low-dose and  $P$  less than 0.001 in the high-dose groups). The incidence of hepatocellular carcinomas alone was significantly ( $P=0.003$ ) increased in the high-dose female rats in comparison to controls.

Carcinomas or adenomas of the pituitary in male rats were observed in a statistically significant negative relation to dose. The Cochran-Armitage test for linear trend was statistically significant in the negative direction ( $P=0.012$ ) and the Fisher exact test between the high-dose group and the control group was significant in the negative direction ( $P=0.012$ ).

In female rats, carcinomas or adenomas of the pituitary gland were observed in decreased proportion in the low-dose group compared with the other two groups. While the Fisher exact test between the low-dose group and the control group was significant ( $P=0.017$ ), no significant difference from the control group was observed in the high-dose group.

C-cell carcinomas or adenomas of the thyroid in male rats were observed in decreased incidence in the dosed groups compared with the control group. The Cochran-Armitage test for linear trend was statistically significant in the negative direction ( $P=0.019$ ), and the Fisher exact test between the high-dose group and the control group indicated a value of  $P=0.031$ , which is above the value of  $P=0.025$  required by the Bonferroni inequality criterion for an overall significance of  $P=0.05$  when two dosed groups are compared with a common control group. In female rats, this tumor was not observed in statistically significant proportions.

Interstitial-cell tumors of the testis were observed in a statistically significant negative relation to dose. The Cochran-Armitage test for linear trend was statistically significant in the negative direction ( $P$  less than 0.001). The Fisher exact test between the high-dose group and the control group was significant ( $P$  less than 0.001). No significant difference from the control group was observed in the low-dose group. It should be noted that the pathologic findings include a statistically significant increase in degeneration in the seminiferous tubule (testis) in male rats. The incidences of this lesion are: 1/49 (2.0%) in the control, 2/44 (5%) in the low-dose, and 43/48 (90%) in the high-dose groups.

Fibroadenomas of the mammary gland in female rats were observed in decreased incidence in the high-dose group. The Fisher exact test between the high-dose group and the control group indicated a value of  $P=0.036$ , but

this value is above the  $P=0.025$  required by the Bonferroni inequality criterion for an overall significance of  $P=0.05$  when two dosed groups are compared with a common control group.

Since only one rat in the entire study died before week 52, time-adjusted analysis eliminating the rat that died before 52 weeks produced essentially no change in the statistical analysis. Similarly, the analysis of tumor incidence by life table methods did not materially alter the significance of differences reported in Tables 11 and 12.

Statistically, the incidences of liver tumors in male and female F344 rats were increased by the administration of di(2-ethylhexyl)phthalate.

Table 11. Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

Topography: Morphology	Control	Low Dose	High Dose
<hr/>			
Hematopoietic System: Myelomonocytic Leukemia (b)	13/50(26)	20/50(40)	17/50(34)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.538	1.308
Lower Limit		0.825	0.674
Upper Limit		2.960	2.597
Weeks to First Observed Tumor	92	82	85
<hr/>			
Hematopoietic System: Leukemia or Lymphoma (e)	14/50(26)	21/50(42)	17/50(34)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.500	1.214
Lower Limit		0.828	0.636
Upper Limit		2.789	2.354
Weeks to First Observed Tumor	95	76	85
<hr/>			
Liver: Hepatocellular Carcinoma (b)	1/50(2)	1/49(2)	5/49(10)
P Values (c),(d)	P=0.047	N.S.	N.S.
Relative Risk (Control) (e)		1.020	5.102
Lower Limit		0.013	0.601
Upper Limit		78.488	236.025
Weeks to First Observed Tumor	105	105	101
<hr/>			

Table 11. Analyses of the Incidence of Primary Tumors in Male Rats  
Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

Topography: Morphology	Control	Low Dose	High Dose
Liver: Neoplastic Nodule (b)	2/50(4)	5/49(10)	7/49(14)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		2.551	3.571
Lower Limit		0.441	0.723
Upper Limit		25.786	33.856
Weeks to First Observed Tumor	103	88	104
Liver: Hepatocellular Carcinoma or Neoplastic Nodule (b)	3/50(6)	6/49(12)	12/49(24)
P Values (c),(d)	P=0.007	N.S.	P=0.010
Relative Risk (Control) (e)		2.041	4.082
Lower Limit		0.464	1.190
Upper Limit		11.991	21.269
Weeks to First Observed Tumor	103	88	101
Pituitary: Carcinoma, NOS (b)	4/46(9)	1/43(2)	0/49(0)
P Values (c),(d)	P=0.024(N)	N.S.	N.S.
Relative Risk (Control) (e)		0.267	0.000
Lower Limit		0.006	0.000
Upper Limit		2.562	1.012
Weeks to First Observed Tumor	78	105	--

Table 11. Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

Topography: Morphology	Control	Low Dose	High Dose
Pituitary: Carcinoma or Adenoma, NOS (b)	8/46(17)	6/43(14)	1/49(2)
P Values (c),(d)	P=0.012(N)	N.S.	P=0.012(N)
Relative Risk (Control) (e)		0.802	0.117
Lower Limit		0.249	0.003
Upper Limit		2.412	0.824
Weeks to First Observed Tumor	78	93	92
Thyroid: C-cell Carcinoma (b)	4/48(8)	1/47(2)	0/46(0)
P Values (c),(d)	P=0.028(N)	N.S.	N.S.
Relative Risk (Control) (e)		0.255	0.000
Lower Limit		0.005	0.000
Upper Limit		2.456	1.123
Weeks to First Observed Tumor	78	100	--
Thyroid: C-cell Carcinoma or Adenoma (b)	5/48(10)	2/47(4)	0/46(0)
P Values (c),(d)	P=0.019(N)	N.S.	P=0.031(N)
Relative Risk (Control) (e)		0.409	0.000
Lower Limit		0.040	0.000
Upper Limit		2.355	0.825
Weeks to First Observed Tumor	78	100	--

Table 11. Analyses of the Incidence of Primary Tumors in Male Rats Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

Topography: Morphology	Control	Low Dose	High Dose
Testis: Interstitial Cell Tumor (b)	47/49(96)	42/44(95)	11/48(23)
P Values (c),(d)	P < 0.001(N)	N.S.	P < 0.001(N)
Departure from Linear Trend (f)	P < 0.001		
Relative Risk (Control) (e)		0.995	0.239
Lower Limit		0.921	0.194
Upper Limit		1.075	0.358
Weeks to First Observed Tumor	85	66	95

- (a) Dosed groups received doses of 6,000 or 12,000 ppm in feed.
- (b) Number of tumor-bearing animals/number of animals examined at site (percent).
- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.
- (f) The probability level for departure from linear trend is given when P is less than 0.05 for any comparison.

Table 12. Analyses of the Incidence of Primary Tumors in Female Rats Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

Topography: Morphology	Control	Low Dose	High Dose
<b>Hematopoietic System:</b>			
Myelomonocytic Leukemia (b)	10/50(20)	14/50(28)	17/50(34)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.400	1.700
Lower Limit		0.642	0.821
Upper Limit		3.177	3.719
Weeks to First Observed Tumor	90	66	94
<b>Liver: Hepatocellular Carcinoma (b)</b>			
	0/50(0)	2/49(4)	8/50(16)
P Values (c),(d)	P=0.002	N.S.	P=0.003
Relative Risk (Control) (e)		Infinite	Infinite
Lower Limit		0.302	2.284
Upper Limit		Infinite	Infinite
Weeks to First Observed Tumor	--	93	95
<b>Liver: Neoplastic Nodule (b)</b>			
	0/50(0)	4/49(8)	5/50(10)
P Values (c),(d)	P=0.030	N.S.	P=0.028
Relative Risk (Control) (e)		Infinite	Infinite
Lower Limit		0.946	1.261
Upper Limit		Infinite	Infinite
Weeks to First Observed Tumor	--	105	105



Table 12. Analyses of the Incidence of Primary Tumors in Female Rats  
Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

Topography: Morphology	Control	Low Dose	High Dose
Liver: Hepatocellular Carcinoma or Neoplastic Nodule (b)	0/50(0)	6/49(12)	13/50(26)
P Values (c),(d)	P < 0.001	P=0.012	P < 0.001
Relative Risk (Control) (e)		Infinite	Infinite
Lower Limit		1.633	4.014
Upper Limit		Infinite	Infinite
Weeks to First Observed Tumor	--	93	95
Pituitary: Carcinoma, NOS	4/47(9)	1/47(2)	2/48(4)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		0.250	0.490
Lower Limit		0.005	0.046
Upper Limit		2.404	3.241
Weeks to First Observed Tumor	105	84	105
Pituitary: Carcinoma, NOS or Adenoma, NOS (b)	24/47(51)	13/47(28)	20/48(42)
P Values (c),(d)	N.S.	P=0.017(N)	N.S.
Departure From Linear Trend (f)	P=0.032		
Relative Risk (Control) (e)		0.542	0.816
Lower Limit		0.296	0.506
Upper Limit		0.960	1.314
Weeks to First Observed Tumor	76	93	69

Table 12. Analyses of the Incidence of Primary Tumors in Female Rats  
Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

Topography: Morphology	Control	Low Dose	High Dose
Mammary Gland: Fibroadenoma (b)	10/50(20)	16/50(32)	3/50(6)
P Values (c),(d)	P=0.050(N)	N.S.	P=0.036(N)
Departure From Linear Trend (f)	P=0.006		
Relative Risk (Control) (e)		1.600	0.300
Lower Limit		0.761	0.056
Upper Limit		3.540	1.083
Weeks to First Observed Tumor	101	74	75
Clitoral Gland: Carcinoma, NOS (b)	4/50(8)	1/50(2)	1/50(2)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		0.250	0.250
Lower Limit		0.005	0.005
Upper Limit		2.411	2.411
Weeks to First Observed Tumor	105	105	105
Uterus: Endometrial Stromal Polyp (b)	7/49(14)	13/50(26)	13/50(26)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.820	1.820
Lower Limit		0.742	0.742
Upper Limit		4.929	4.929
Weeks to First Observed Tumor	101	62	69

Table 12. Analyses of the Incidence of Primary Tumors in Female Rats  
Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

---

- (a) Dosed groups received doses of 6,000 or 12,000 ppm in feed.
- (b) Number of tumor-bearing animals/number of animals examined at site (percent).
- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.
- (f) The probability level for departure from linear trend is given when P is less than 0.05 for any comparison.



#### IV. RESULTS - MICE

##### A. Body Weights, Food Consumption, and Clinical Signs (Mice)



A dose-related decrease in mean body weight gain in female mice was observed from week 25 to the end of the study (Figure 3). Daily mean food consumptions were similar among control and dosed groups throughout the study (Tables 13 and 14). The average daily food consumption per mouse was 100% and 96% that of controls for low-dose males and females, respectively, and 96% and 100% for high-dose males and females, respectively. Mean daily doses of di(2-ethylhexyl)phthalate as g per kg body weight were 0.672 and 1.325 for low- and high-dose males, respectively, and 0.799 and 1.821 for low- and high-dose females, respectively. No other compound-related clinical signs of toxicity were reported.

##### B. Survival (Mice)

Estimates of the probabilities of survival of male and female mice administered di(2-ethylhexyl)phthalate in feed at the concentrations of this bioassay, together with those of control group, are shown by the Kaplan and Meier curves in Figure 4. No positive trends in mortality were observed. Several deaths in the male control group at 19-21 weeks resulted in shortened survival in that group when compared with the dosed groups. The low-dose female mice had significantly shortened survival compared with that in the control group ( $P=0.006$ ), but no positive trend was observed since there was somewhat longer survival in the high-dose group than in the low-dose group.

In male mice, 34/50 (68%) of the control, 38/50 (76%) of the low-dose and 35/50 (70%) of the high-dose groups lived to the end of the study at 104 weeks. In female mice, 39/50 (78%) of the control, 25/50 (50%) of the low-dose, and 33/50 (66%) of the high-dose groups lived to the end of the study at 104 weeks.

A sufficient number of mice were at risk for the development of late-appearing tumors.



**Figure 3. Growth Curves for Mice Fed Diets Containing Di(2-ethylhexyl)phthalate**

Table 13. Feed and Compound Consumption in Male B6C3F1 Mice Receiving Di(2-ethylhexyl)phthalate

Week	Control		Low				High			
	Grams Feed/ Day(a)	Body Weight (grams)	Grams Feed/ Day(a)	Body Weight (grams)	Low Control (b)	Dose/ Day (c)	Grams Feed/ Day(a)	Body Weight (grams)	High/ Control (b)	Dose/ Day (c)
Male										
8	8.0	29	8.6	28	1.1	0.918	7.9	28	1.0	1.684
12	8.0	30	8.6	30	1.1	0.857	7.9	30	1.0	1.571
16	8.6	32	8.6	32	1.0	0.804	9.1	32	1.1	1.714
20	8.6	35	7.9	34	0.9	0.693	7.7	34	0.9	1.361
24	9.1	38	8.1	35	0.9	0.698	7.7	35	0.8	1.322
28	8.0	37	8.4	37	1.1	0.683	7.3	36	0.9	1.214
32	8.1	38	7.1	38	0.9	0.564	7.1	36	0.9	1.190
36	7.7	39	8.3	37	1.1	0.672	10.1	37	1.3	1.645
40	7.9	40	7.6	39	1.0	0.582	6.9	38	0.9	1.083
44	6.4	42	3.4	41	0.5	0.251	6.6	38	1.0	1.038
48	4.9	42	5.1	41	1.1	0.376	5.0	39	1.0	0.769
53	7.1	43	8.4	41	1.2	0.617	7.3	39	1.0	1.121
56	7.9	43	8.1	41	1.0	0.596	6.1	39	0.8	0.945
60	8.0	42	8.0	42	1.0	0.571	7.6	41	0.9	1.108
64	7.9	43	8.1	42	1.0	0.582	6.9	40	0.9	1.029
68	8.9	43	7.6	42	0.9	0.541	7.9	40	0.9	1.179
72	9.4	43	9.0	42	1.0	0.643	7.9	40	0.8	1.179
76	9.6	42	9.9	40	1.0	0.739	8.7	39	0.9	1.341
80	8.9	38	8.9	35	1.0	0.759	7.9	36	0.9	1.310
84	10.6	42	9.3	40	0.9	0.696	8.6	39	0.8	1.319
88	10.9	43	9.3	39	0.9	0.714	9.6	39	0.9	1.473
92	11.0	42	10.1	38	0.9	0.801	10.1	38	0.9	1.602
96	9.0	42	13.0	39	1.4	1.000	11.0	39	1.2	1.692
100	7.7	42	10.0	39	1.3	0.769	12.1	38	1.6	1.917
Mean	8.4	40	8.4	38	1.0	0.672	8.1	37	1.0	1.325
SD (d)	1.3	4.2	1.7	3.9	0.2	0.160	1.6	3.3	0.2	0.285
CV (e)	15.5	10.5	20.2	10.3	20.0	23.8	19.8	8.9	20.0	21.5

(a) Grams of feed consumed per animal per day.

(b) Grams of feed per day for the dosed group divided by the same value for the controls.

(c) Grams of compound consumed per day per kg of body weight.

(d) Standard Deviation

(e) Coefficient of Variation (standard deviation/mean x 100).

Table 14. Feed and Compound Consumption in Female B6C3F1 Mice Receiving Di(2-ethylhexyl)phthalate

Week	Control		Low				High			
	Grams Feed/ Day(a)	Body Weight (grams)	Grams Feed/ Day(a)	Body Weight (grams)	Low Control (b)	Dose/ Day (c)	Grams Feed/ Day(a)	Body Weight (grams)	High/ Control (b)	Dose/ Day (c)
Female										
8	9.0	21	9.1	21	1.0	1.306	9.4	22	1.0	2.571
12	9.9	24	9.9	23	1.0	1.286	9.4	24	1.0	2.357
16	10.7	25	9.7	25	0.9	1.166	11.0	25	1.0	2.640
20	9.6	27	8.6	27	0.9	0.952	8.7	27	0.9	1.937
24	10.1	29	9.6	28	0.9	1.026	9.7	27	1.0	2.159
28	9.1	35	8.1	28	0.9	0.872	9.1	28	1.0	1.959
32	9.0	33	7.3	29	0.8	0.754	7.9	29	0.9	1.626
36	8.4	33	8.1	30	1.0	0.814	8.6	28	1.0	1.837
40	8.6	36	7.9	32	0.9	0.737	7.9	29	0.9	1.626
44	5.9	38	3.3	35	0.6	0.282	5.6	30	1.0	1.114
48	5.6	39	4.1	34	0.7	0.366	4.9	30	0.9	0.971
53	8.6	41	7.3	36	0.8	0.607	8.6	32	1.0	1.607
56	8.6	41	8.3	36	1.0	0.690	9.1	30	1.1	1.829
60	7.3	43	7.6	37	1.0	0.614	9.1	32	1.3	1.714
64	8.0	44	7.9	38	1.0	0.620	9.0	32	1.1	1.688
68	8.7	45	8.6	38	1.0	0.677	5.1	32	0.6	0.964
72	9.1	45	9.1	38	1.0	0.722	10.1	33	1.1	1.844
76	9.7	46	10.6	39	1.1	0.813	9.3	33	1.0	1.688
80	9.4	45	9.6	40	1.0	0.718	8.4	32	0.9	1.580
84	9.4	47	9.1	39	1.0	0.703	7.6	33	0.8	1.377
88	9.7	48	10.9	38	1.1	0.857	9.6	34	1.0	1.689
92	10.6	47	10.6	38	1.0	0.835	11.7	33	1.1	2.130
96	10.7	47	11.0	37	1.0	0.892	12.0	32	1.1	2.250
100	9.6	48	11.0	38	1.1	0.868	13.6	32	1.4	2.545
Mean	9.0	39	8.6	34	1.0	0.799	9.0	30	1.0	1.821
SD (d)	1.3	8.5	1.9	5.7	0.1	0.241	2.0	3.2	0.2	0.460
CV (e)	14.4	21.8	22.1	16.8	10.0	30.2	22.2	10.7	20.0	25.3

(a) Grams of feed consumed per animal per day.



(b) Grams of feed per day for the dosed group divided by the same value for the controls.

(c) Grams of compound consumed per day per kg of body weight.

(d) Standard Deviation

(e) Coefficient of Variation (standard deviation/mean x 100).





**Figure 4. Survival Curves for Mice Fed Diets Containing Di(2-ethylhexyl)phthalate**

### C. Pathology (Mice)

Histopathologic findings on neoplasms in mice are summarized in Appendix B, Tables B1 and B2; findings on nonneoplastic lesions are summarized in Appendix D, Tables D1 and D2.

Hepatocellular carcinomas were observed at an increased incidence in high-dose males (19/50, 38%) and in both low- (7/50, 14%) and high-dose females (17/50, 34%). The incidence was 9/50 (18%) in control males and 0/50 in control females. The combined incidence of hepatocellular carcinoma and hepatocellular adenoma was elevated in low- (25/48, 52%) and high-dose (29/50, 58%) males and low- (12/50, 24%) and high-dose (18/50, 36%) females. Male controls had a combined incidence of 14/50 (28%), while female control values were 1/50 (2%). Multiple liver tumors occurred more frequently in dosed mice than in controls.

Hepatocellular adenomas were fairly large, expanding, well-differentiated tumors that caused compression of the adjacent hepatic parenchyma. Tumor cells were larger than normal hepatocytes, and many were composed of hepatocytes with basophilic cytoplasm. Some adenomas had hepatocytes with eosinophilic, vacuolated, or clear cytoplasm. Clear cell foci also occurred within adenomas.

Hepatocellular carcinomas had solid areas, trabecular and papillary formations, sinusoidal ectasia, necrosis, hemorrhage, thrombosis, and calcification. There was considerable pleomorphism characterized by many large hyperchromatic bizarre nuclei and by variation in cell size.

Cytoplasm was usually basophilic, while hyaline droplets (inclusions) and fatty vacuoles were common. Dosed mice of both sexes had pulmonary metastases. Metastatic hepatocellular carcinoma was found in seven low-dose and five high-dose males and in two low-dose and seven high-dose females. The primary liver tumors of these mice were always of the trabecular type. No metastatic hepatocellular carcinoma occurred in the lungs of control mice of either sex. Toxic hepatic lesions were not observed in dosed mice.

Bilateral tubular degeneration of the testes was seen in 14% of the high-dose males. This lesion was observed in one control male and in two low-dose males.

The usual inflammatory and other degenerative lesions commonly found in this strain of mouse were seen in comparable numbers in dosed groups and controls. None were judged to be compound related.

Histopathologic examination indicated that, under the conditions of this bioassay, administration of di(2-ethylhexyl)phthalate was associated with an increased incidence of liver tumors in B6C3F1 mice.

#### D. Statistical Analyses of Results (Mice)

Tables 15 and 16 contain the statistical analyses of those primary tumors that occurred in at least two animals of one group and with an incidence of at least 5% in one or more groups.


A statistically significant positive dose-related trend was observed for hepatocellular carcinomas in male mice. The Cochran-Armitage test indicated a probability level of  $P=0.018$  for linear trend in males (9/50, 18% in the control; 14/48, 29% in the low-dose; and 19/50, 38% in the high-dose group). The Fisher exact test between the high-dose group and the control group was significant ( $P=0.02$ ). A statistically significant positive dose-related trend was also observed for hepatocellular carcinomas alone in female mice. The Cochran-Armitage test indicated a probability level of less than 0.001 for linear trend in females (0/50 in the control; 7/50, 14% in the low-dose; and 17/50, 34% in the high-dose group). The Fisher exact tests were also significant ( $P=0.006$  between low-dose and control groups and  $P$  less than 0.001 between high-dose and control groups).

Hepatocellular carcinomas or adenomas of the liver in either sex of mice were observed in a statistically significant positive relation to dose in that results of the Cochran-Armitage test values indicated a probability level of  $P=0.002$  for linear trend in males (14/50, 28% in the control; 25/48, 52% in the low-dose; and 29/50, 58% in the high-dose groups). The Fisher exact test between the high-dose group and the control group was significant ( $P=0.002$ ), and also a significant incidence was observed in the low-dose male group ( $P=0.013$ ). The incidences of hepatocellular carcinomas or adenomas in the other male control groups concurrently on test in the room used for the di(2-ethylhexyl)phthalate study were: guar gum (16/50, 32%), butyl benzyl


phthalate (13/50, 26%), and di(2-ethylhexyl)adipate (13/50, 26%), compared with 14/50 (28%) in the control for the present study, indicating that the incidence of these tumors in the controls of this study was within a normal range. Hepatocellular carcinomas or adenomas of the liver in female mice were observed in a statistically significant positive relation to dose in the dosed groups compared with the control group: 1/50 (2%) in the controls, 12/50 (24%) in the low-dose, and 18/50 (36%) in the high-dose groups. The Cochran-Armitage test for linear trend was significant (P less than 0.001) and the Fisher exact tests were significant (P less than or equal to 0.001) in either group.

For liver tumors in mice, the estimated probabilities of remaining tumor-free in the absence of competing risk are shown in Figure 5 and 6. There is a significant (P less than 0.001) trend in the incidence of the tumors in female mice and (P=0.009) in male mice as determined by life-table methods. A time-adjusted analysis was made eliminating those animals that died before 52 weeks on study. The new incidences of male mice with liver tumors were 14/45(31%) in the controls, 25/45(56%) in the low-dose group, and 29/49(59%) in the high-dose group. This analysis indicated a P value for trend of P=0.007, and for the Fisher exact tests the probability levels were P=0.016 (low-dose) and P=0.007 (high-dose). Therefore, this time adjusted analysis does not materially affect the results reported in the previous paragraphs.

Statistically, the incidences of liver tumors in male and female B6C3F1 mice were increased by the administration of di(2-ethylhexyl)phthalate.



**Figure 5. Life Table for Male Mice Fed Diets Containing Di(2-ethylhexyl)phthalate: Liver Tumors.**



**Figure 6. Life Table for Female Mice Fed Diets Containing Di(2-ethylhexyl)phthalate: Liver Tumors**

Table 15. Analyses of the Incidence of Primary Tumors in Male Mice Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

Topography: Morphology	Control	Low Dose	High Dose
Lung: Alveolar/Bronchiolar Carcinoma (b)	4/50(8)	3/49(6)	2/50(4)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		0.765	0.500
Lower Limit		0.118	0.047
Upper Limit		4.288	3.318
Weeks to First Observed Tumor	105	70	104
Lung: Alveolar/Bronchiolar Carcinoma or Adenoma (b)	10/50(20)	9/49(18)	7/50(14)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		0.918	0.700
Lower Limit		0.362	0.246
Upper Limit		2.292	1.869
Weeks to First Observed Tumor	83	70	104
Hematopoietic System: Lymphoma (b)	8/50(16)	8/49(16)	8/50(16)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.020	1.000
Lower Limit		0.363	0.355
Upper Limit		2.869	2.815
Weeks to First Observed Tumor	100	88	87

Table 15. Analyses of the Incidence of Primary Tumors in Male Mice Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

Topography: Morphology	Control	Low Dose	High Dose
Liver: Hepatocellular Carcinoma (b)	9/50(18)	14/48(29)	19/50(38)
P Values (c),(d)	P=0.018	N.S.	P=0.022
Relative Risk (Control) (e)		1.620	2.111
Lower Limit		0.724	1.017
Upper Limit		3.828	4.737
Weeks to First Observed Tumor	65	70	72
Liver: Hepatocellular Adenoma (b)	6/50(12)	11/48(23)	10/50(20)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.910	1.667
Lower Limit		0.706	0.597
Upper Limit		5.793	5.164
Weeks to First Observed Tumor	105	105	104
Liver: Hepatocellular Carcinoma or Adenoma	14/50(28)	25/48(52)	29/50(58)
P Values (c),(d)	P=0.002	P=0.013	P=0.002
Relative Risk (Control) (e)		1.860	2.071
Lower Limit		1.070	1.226
Upper Limit		3.315	3.597
Weeks to First Observed Tumor	65	70	72



Table 15. Analyses of the Incidence of Primary Tumors in Male Mice  
Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

---

- (a) Dosed groups received doses of 3,000 or 6,000 ppm in feed.
- (b) Number of tumor-bearing animals/number of animals examined at site (percent).
- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.

Table 16. Analyses of the Incidence of Primary Tumors in Female Mice Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

Topography: Morphology	Control	Low Dose	High Dose
<b>Hematopoietic System:</b>			
Lymphomas (b)	10/50(20)	18/50(36)	15/50(30)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.800	1.500
Lower Limit		0.882	0.701
Upper Limit		3.897	3.359
Weeks to First Observed Tumor	83	85	48
<b>Circulatory System:</b>			
Hemangioma (b)	3/50(6)	1/50(2)	0/50(0)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		0.333	0.000
Lower Limit		0.006	0.000
Upper Limit		3.983	1.663
Weeks to First Observed Tumor	103	104	--
<b>Liver: Hepatocellular</b>			
Carcinoma (b)	0/50(0)	7/50(14)	17/50(34)
P Values (c),(d)	P < 0.001	P=0.006	P < 0.001
Relative Risk (Control) (e)		Infinite	Infinite
Lower Limit		1.941	5.408
Upper Limit		Infinite	Infinite
Weeks to First Observed Tumor	--	79	62

Table 16. Analyses of the Incidence of Primary Tumors in Female Mice Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

Topography: Morphology	Control	Low Dose	High Dose
Liver: Hepatocellular Adenoma (b)	1/50(2)	5/50(10)	1/50(2)
P Values (c),(d)	N.S.	N.S.	N.S.
Departure From Linear Trend (f)	P=0.028		
Relative Risk (Control) (e)		5.000	1.000
Lower Limit		0.588	0.013
Upper Limit		231.346	76.970
Weeks to First Observed Tumor	105	105	105
Liver: Hepatocellular Carcinoma or Adenoma (b)	1/50(2)	12/50(24)	18/50(36)
P Values (c),(d)	P < 0.001	P=0.001	P < 0.001
Relative Risk (Control) (e)		12.000	18.000
Lower Limit		1.891	3.047
Upper Limit		499.771	726.973
Weeks to First Observed Tumor	105	79	62
Mammary Gland: Adenocarcinoma, NOS (b)	2/50(4)	3/50(6)	3/50(6)
P Values (c),(d)	N.S.	N.S.	N.S.
Relative Risk (Control) (e)		1.500	1.500
Lower Limit		0.180	0.180
Upper Limit		17.329	17.329
Weeks to First Observed Tumor	105	87	85

Table 16. Analyses of the Incidence of Primary Tumors in Female Mice  
Fed Diets Containing Di(2-ethylhexyl)phthalate (a)

(Continued)

---

- (a) Dosed groups received doses of 3,000 or 6,000 ppm in feed.
- (b) Number of tumor-bearing animals/number of animals examined at site (percent).
- (c) Beneath the incidence of tumors in the control group is the probability level for the Cochran-Armitage test when P is less than 0.05; otherwise, not significant (N.S.) is indicated. Beneath the incidence of tumors in a dosed group is the probability level for the Fisher exact test for the comparison of that dosed group with the control group when P is less than 0.05; otherwise, not significant (N.S.) is indicated.
- (d) A negative trend (N) indicates a lower incidence in a dosed group than in a control group.
- (e) The 95 percent confidence interval of the relative risk between each dosed group and the control group.
- (f) The probability level for departure from linear trend is given when P is less than 0.05 for any comparison.

## V. DISCUSSION

Minimal-to-moderate decreases in body weight gain occurred in some groups of treated animals, most notably female mice. It is not believed, however, that such a decrease in body weight gain in the treated animals weakens the conclusions of this study, since liver tumors occurred also in groups that did not exhibit excessive decreases in body weight gain, and because di(2-ethylhexyl)phthalate did not decrease lifespan in either male or female rats or mice. According to modern standards, a maximum tolerated dose (MTD) is:

...the highest dose of the test agent given during the chronic study that can be predicted not to alter the animal's normal longevity from effects other than carcinogenicity. Since these data may not always be easily interpretable, a degree of judgement is often necessary in estimating the MTD. The MTD should be the highest dose that causes no more than a 10% weight decrement (although a depressed weight gain is a clinical sign of toxicity, this particular effect is acceptable when estimating the MTD), as compared to the appropriate control groups; and does not produce mortality, clinical signs of toxicity or pathological lesions (other than those that may be related to a neoplastic response) that would be predicted to shorten the animal's natural life span. (Sontag et al., 1976).

Because individual body weights were not recorded in this study, it is impossible to discern whether or not decreased weight gain occurred secondary to the development of liver tumors and was, therefore, related to the neoplastic response. Even if tumorigenicity were not the cause of the decreased weight gain, it must be emphasized that the 10% weight differential is only a guideline. Moreover, it is to be assessed during the prechronic phase of the study, not during the chronic phase, unless two lifetime bioassays are to be performed -- the former to set the dose for the latter (Federal Register, 1980). There is, in fact, no precise definition of MTD. The primary reason for not surpassing the theoretical MTD in chronic studies is that early deaths could preclude tumor formation. Alternatively, tumors might be formed secondary to non-specific effects such as irritation (e.g., bladder stones and diethylene glycol), tissue damage (e.g., liver cirrhosis and alcohol), or tissue hyperplasia (e.g., thyroid

hyperplasia and goitrogens) (Federal Register, 1980). The absence of early deaths or significant pathological changes in the liver other than neoplasia in this study indicates that tumor development was directly related to the biological effects of di(2-ethylhexyl)phthalate and that a maximally tolerated dose, for the purpose of carcinogenicity testing, was not exceeded.

Liver tumors were associated with the administration of di(2-ethylhexyl)-phthalate in both rats and mice of either sex. Hepatocellular carcinomas or neoplastic nodules in high-dose rats of either sex and in low-dose female rats, and hepatocellular carcinomas or adenomas in low- and high-dose mice of either sex occurred at incidences significantly higher than those in the controls. Hepatocellular carcinomas alone were observed at statistically significant increased incidences in high-dose female rats, high-dose male mice, and in both high-dose and low-dose female mice in comparison to controls. Twenty-one of the 57 hepatocellular carcinomas in treated mice (both sexes) gave rise to pulmonary metastases. There were no lung metastases in control in mice or in any rats.

Recent evidence indicates species differences in the metabolism of di(2-ethylhexyl)phthalate. While humans and African Green monkeys glucuronidate the hydrolysis product of di(2-ethylhexyl)phthalate, mono(2-ethylhexyl)phthalate, at the free carboxylate group, rats do not and must perform successive oxidation reactions to produce a molecule sufficiently polar for urinary excretion (Albro, et al., 1973; 1981; Peck et al., 1978). The importance of this species difference in di(2-ethylhexyl)phthalate metabolism relative to extrapolation of the carcinogenic potential in rats to that in humans awaits elucidation of a probable mechanism of tumorigenic action. Moreover, it is not clear at the present time whether mice, a species that also develops tumors, metabolize di(2-ethylhexyl)phthalate in a manner similar to rats or to primate species.

Clear cell cytoplasmic change, usually occurring in multiple foci, was observed more frequently in low- and high-dose male rats than in controls. No other compound related non-neoplastic liver lesions were observed in the present study. Hepatomegaly, as reported by Lake et al. (1975) in rats fed

similar concentrations of di(2-ethylhexyl)phthalate in the diet, was not detected grossly or histologically in this study. However, the absolute or relative weights of the liver were not specifically measured.

Carcinogenic effects of di(2-ethylhexyl)phthalate were not reported in previous chronic studies utilizing Sherman or Wistar rats (Carpenter et al., 1953; Harris et al., 1956). As discussed earlier, however, these studies were insufficient, by current standards, for assessing carcinogenic potential due to small group size, poor survival, and incomplete reporting. Thus, the results of the bioassay of di(2-ethylhexyl)phthalate reported herein are not in conflict with previous studies of chronic di(2-ethylhexyl)phthalate toxicity.

Hypertrophy of cells in the anterior pituitary, seminiferous degeneration, and atrophy were seen in male rats in the subchronic study as well as in rats in other feeding studies with di(2-ethylhexyl)phthalate (Gray et al., 1977). The hypertrophy of cells in the anterior pituitary is descriptively similar to the "castration cells" in the pars distalis reported by Gray et al. (1977) in rats fed diets containing 1% or 2% di(2-ethylhexyl)phthalate for 17 weeks. The observed testicular atrophy and cellular hypertrophy of the pituitary could be causally related. (Likewise, the decreased incidence of tumors of the thyroid, pituitary, and testis could be correlated with increased endocrine activity of the pituitary gland.)

Two other plasticizers chemically related to di(2-ethylhexyl)phthalate were on test concurrently in the same room as di(2-ethylhexyl)phthalate. Butyl benzyl phthalate was not found to be carcinogenic for male or female B6C3F1 mice, but was associated with an increased incidence of leukemia in female F344 rats (NTP, in press). Di(2-ethylhexyl)adipate was not carcinogenic for F344 rats of either sex. DEHA was carcinogenic for female B6C3F1 mice, causing increased incidences of hepatocellular carcinomas, and was probably carcinogenic for male B6C3F1 mice, causing an increased incidence of hepatocellular adenomas (NTP, 1981).

Two other compounds structurally related to di(2-ethylhexyl)phthalate (phthalamide and phthalic anhydride) were tested in the Bioassay Program and were not found to be carcinogenic for male or female F344 rats or for male or female B6C3F1 mice (NCI, 1979b; NCI, 1979c). Administration of dimethylterephthalate to mice resulted in a dose-related trend for increased incidences of lung neoplasia in male and for lymphoma or leukemia in female B6C3F1 mice (NCI, 1979a). These lesions, however, were judged to be of equivocal biological significance. Results of these studies are summarized in Table 17.



Table 17. Comparison of Target Organs Affected in Chronic Bioassays of Some Compounds Structurally Related to Di(2-ethylhexyl)phthalate

Compound	Species	Sex	Dose (ppm)	Duration (Weeks)	Liver	Testes	Pituitary	Lymphoma or Leukemia	Urinary Bladder	Lung
Di(2-ethylhexyl)phthalate (Carpenter, 1953)	Rats (Sherman)	M	4,000	104	-	-	-	-	-	-
		F	4,000	104	-	-	-	-	-	-
Di(2-ethylhexyl)phthalate (Harris, 1956)	Rats (Wistar)	M	5,000	103	-	-	-	-	-	-
		F	5,000	103	-	-	-	-	-	-
Di(2-ethylhexyl)phthalate (Current Study)	Rats (F344)	M	12,000	103	N (r)	T (b)	T	-	-	-
		F	12,000	103	N	-	-	-	-	-
Di(2-ethylhexyl)phthalate (Current Study)	Mice (B6C3F1)	M	6,000	103	N	-	-	-	-	-
		F	6,000	103	N	-	-	-	-	-
Butyl benzyl phthalate (NTP, in press)	Rats (F344)	M	Not adequately tested		-	-	-	-	-	-
		F	12,000	103	-	-	-	N	-	-
Butyl benzyl phthalate (NTP, in press)	Mice (B6C3F1)	M	12,000	103	-	-	-	-	-	-
		F	12,000	103	-	-	-	-	-	-
Phthalamide (NCI, 1979b)	Rats (F344)	M	30,000	106	T	-	-	-	T	-
		F	10,000	106	T	-	-	-	-	-
Phthalamide (NCI, 1979b)	Mice (B6C3F1)	M	50,000	104	-	-	-	-	-	-
		F	25,000	104	-	-	-	-	T	-
Phthalic anhydride (NCI, 1979c)	Rats (F344)	M	15,000	105	-	-	-	-	-	-
		F	15,000	105	-	-	-	-	-	D (c)
Phthalic anhydride (NCI, 1979c)	Mice (B6C3F1)	M	32,000 (d)	104	-	-	-	-	-	-
		F	24,000 (d)	104	-	-	-	-	-	-

Table 17. Comparison of Target Organs Affected in Chronic Bioassays of Some Compounds Structurally Related to Di(2-ethylhexyl)phthalate  
(Continued)

Compound	Species	Sex	Dose (ppm)	Duration (Weeks)	Liver	Testes	Pituitary	Lymphoma or Leukemia		Urinary Bladder	Lung
								Lymphoma	Leukemia		
Dimethyl terephthalate (NCI, 1979a)	Rats (F344)	M	5,000 (e)	103	-	-	-	-	-	-	-
		F	5,000 (e)	103	-	-	-	-	-	-	-
Dimethyl terephthalate (NCI, 1979a)	Mice (B6C3F1)	M	5,000 (e)	103	-	-	-	-	-	-	D
		F	5,000 (e)	103	-	-	-	-	D	-	-
Di(2-ethylhexyl)adipate (NTP, 1981)	Rats (F344)	M	25,000	103	-	-	-	-	-	-	-
		F	25,000	103	-	-	-	-	-	-	-
Di(2-ethylhexyl)adipate (NTP, 1981)	Mice (B6C3F1)	M	25,000	103	N	-	-	-	-	-	-
		F	25,000	103	N	-	-	-	-	-	-

- (a) N = Neoplastic lesion
- (b) T = Toxic lesion
- (c) D = Neoplastic lesion occurred with dose-related trend
- (d) Time weighted average
- (e) May not be maximum tolerated dose

## VI. CONCLUSION

Under the conditions of this bioassay, di(2-ethylhexyl)phthalate was carcinogenic for F344 rats and B6C3F1 mice, causing increased incidences of female rats and male and female mice with hepatocellular carcinomas, and inducing an increased incidence of male rats with either hepatocellular carcinomas or neoplastic nodules.



## VII. BIBLIOGRAPHY

Abe, S. and Sasaki, M., Chromosome aberrations and sister chromatid exchanges in Chinese hamster cells exposed to various chemicals. J. Nat. Cancer Inst. 58:1635-1641, 1977.

Albro, P. W., Hass, J. R., Peck, C. C., Odom, D. G., Corbett, J. T., Bailey, F. J., Blatt, H. E., and Barrett, B. B., Identification of the metabolites of di(2-ethylhexyl)phthalate in urine from the African Green monkey. Drug Metab. Dispos. 9:223-225, 1981.

Albro, P., Thomas, R., and Fishbein, L., Metabolism of diethylhexyl phthalate by rats: Isolation and characterization of the urinary metabolites. J. Chromatogr. 76:321-330, 1973.

Armitage, P., Statistical Methods in Medical Research, John Wiley & Sons, Inc., New York, 1971, pp. 362-365.

Autian, J., Toxicity and health threats of phthalate esters: review of the literature. Environ. Health Perspect. 4:3-26, 1973.

Baker, R., Diethylhexyl phthalate as a factor in blood transfusion and haemodialysis. Toxicology 9:319-329, 1978.

Berenblum, I., ed., Carcinogenicity Testing: A Report of the Panel on Carcinogenicity of the Cancer Research Commission of UICC, Vol. 2., International Union Against Cancer, Geneva, 1969.

Calley, D., Autian, J., and Guess, W., Toxicology of a series of phthalate esters. J. Pharm. Sci. 55:158, 1966.

Carpenter, C., Weil, C., and Smyth, H., Chronic oral toxicity of di(2-ethylhexyl)phthalate for rats, guinea pigs, and dogs. Arch. Ind. Hyg. Occup. Med. 8:219-226, 1953.

CFR, U.S. Code of Federal Regulations 21:121.2514, 1976.

Cox, D. R., Analysis of Binary Data, Methuen & Co., Ltd., London, 1970, pp. 48-52.

Cox, D. R., Regression models and life tables. J. R. Stat. Soc. B34:187-220, 1972.

Daniel, J. and Bratt, H., The absorption, metabolism and tissue distribution of di(2-ethylhexyl)phthalate in rats. Toxicology 2:51-65, 1974.

Federal Register, 39: 23540, 1974.

Federal Register, 45:5091-5094, 1980.

Gart, J. J., The comparison of proportions: a review of significance tests, confidence limits and adjustments for stratification. Rev. Int. Stat. Inst. 39:148-169, 1971.

Gesler, R., Toxicology of di-2-ethylhexyl phthalate and other phthalic acid ester plasticizers. Environ. Health Perspect. 3:73-79, 1973.

Grace, W. R. and Co., Technical information on Hatcol DOP di-2-ethylhexyl phthalate, 1976.

Gray, T., Butterworth, K., Gaunt, I., Grasso, P., and Gangolli, S. Short-term toxicity study of di-(2-ethylhexyl)phthalate in rats. Food Cosmet. Toxicol. 15:389-399, 1977.

Harris, R., Hodge, C., Maynard, E., and Blanchet, H., Chronic oral toxicity of 2-ethylhexyl phthalate in rats and dogs. Arch. Ind. Health 13:259-264, 1956.

Hillman, L. S., Goodwin, S. L., and Sherman, W. R. Identification and measurement of plasticizer in neonatal tissues after umbilical catheters and blood products. N. Engl. J. Med. 292:381-386, 1975.

Hodge, H., Acute toxicity for rats and mice of 2-ethylhexanol and 2-ethylhexyl phthalate. Proc. Soc. Exp. Med. 53:20-23, 1943.

Ishidate, M. and Odashima, S., Chromosome tests with 134 compounds on Chinese hamster cells in vitro -- a screening test for chemical carcinogens. Mutat. Res. 48:337-354, 1977.

Jacobson, M. S., Kevy, S. V., and Grand, R. J. Effects of a plasticizer leached from polyvinylchloride on the subhuman primate: A consequence of chronic transfusion therapy. J. Lab. Clin. Med. 89: 1066-1079, 1977.

Jacobson, M. S., Parkman, R., Button, L. N., Jaeger, R. J., and Kevy, S. V. The toxicity of human serum stored in flexible polyvinylchloride containers on human fibroblast cell cultures: An effect of di-2-ethylhexyl phthalate. Res. Comm. Chem. Path. Pharmacol. 9:315-323, 1974.

Jaeger, R. and Rubin, R., Migration of a phthalate ester plasticizer from polyvinyl chloride blood bags into stored human blood and its localization in human tissues. N. Engl. J. Med. 287:1114-1118, 1972.

Kaplan, E. L. and Meier, P., Nonparametric estimation from incomplete observations. J. Amer. Statist. Assoc. 53:457-481, 1958.

Kirk-Othmer Encyclopedia of Chemical Technology 2nd ed. Vol. 21 Intersciences Publishers, New York, 1970, p. 135.

Korosy, L., Period. Polytech., Chem. Eng. (Budapest), 10(2):103-115, 1966.

- Lake, B., Gangolli, S., Grasso, P., and Lloyd, A., Studies on the hepatic effects of orally administered di-(2-ethylhexyl) phthalate in the rat. Toxicol. Appl. Pharmacol. 32:355-367, 1975.
- Lawrence, W., Malik, M., Turner, J., Singh, A., and Autian, J., A toxicological investigation of some acute, short-term, and chronic effects of administering di-2-ethylhexyl phthalate (DEHP) and other phthalate esters. Environ. Res. 9:1-11, 1975.
- Linhart, M. S., Cooper, J. A., Martin, R. L., Page, N. P., and Peters, J. A., Carcinogenesis bioassay data system. Comp. Biomed. Res. 7:230-248, 1974.
- Miller, R. G., Jr., Simultaneous Statistical Inference, McGraw-Hill Book Co., New York, 1966, pp. 6-10.
- NCI, National Cancer Institute, Bioassay of Dimethyl Terephthalate, DHEW Publication No. (NIH) 79-1376, Carcinogenesis Testing Program, National Cancer Institute, National Institutes of Health, Bethesda, Md., 1979a.
- NCI, National Cancer Institute, Bioassay of Phthalamide, DHEW Publication No. (NIH) 79-1717, Carcinogenesis Testing Program, National Cancer Institute, National Institutes of Health, Bethesda, Md., 1979b.
- NCI, National Cancer Institute, Bioassay of Phthalic Anhydride, DHEW Publication No. (NIH) 79-1715, Carcinogenesis Testing Program, National Cancer Institute, National Institutes of Health, Bethesda, Md., 1979c.
- NTP, National Toxicology Program, Bioassay of Butyl Benzyl Phthalate, DHHS Publication No. (NIH) 81-1769, Carcinogenesis Testing Program, National Toxicology Program, National Institutes of Health, Bethesda, Md., in press.
- NTP, National Toxicology Program, Bioassay of Di(2-ethylhexyl)adipate, DHHS Publication No. (NIH) 81-1768, Carcinogenesis Testing Program, National Toxicology Program, National Institutes of Health, Bethesda, Md., 1981.
- Onda, H., Kodama, H., Yamada, N., and Ota, H., Effect of phthalate ester on reproductive performance in rat. Nippon Eiseigaku Zasshi 31(4):507-512, 1976.
- Ota, H., Onda, H., Kodama, H., and Yamada, N., Histopathological studies on the effect of phthalic acid esters on the biological system of mice. Nippon Eiseigaku Zasshi 29(5):519-524, 1974.
- Patty, F., Industrial Hygiene and Toxicology. Vol.II. Interscience Publishers, New York, 1967, pp. 1904-1906.
- Peck, C. C., Albro, P. W., Hass, J. R., Odom, D. G., Barrett, B. B., and Bailey, F. J., Metabolism and excretion of the plasticizer di-2-ethylhexyl phthalate in man. Clin. Res. 26:101A, 1978.

Petersen, R., Lyman, R., Roll, D., and Swinyard, E., Toxicology of plastic devices having contact with blood. NTIS Publication No. PB-233701. National Technical Information Service, U.S. Department of Commerce, Washington, D.C., 1974.

Reddy, J., Moody, D., Azarnoff, D., and Rao, M., Di-(2-ethylhexyl)phthalate: an industrial plasticizer induces hypolipidemia and enhances hepatic catalase and carnitine acetyltransferase activities in rats and mice. Life Sci. 18:941-946, 1976.

Reith, H., and Eckhardt, H. Freiberger Forschungsh., A, 250:39-86, 1962.

Rowland, I., Metabolism of di-(2-ethylhexyl) phthalate by the contents of the alimentary tract of the rat. Food Cosmet. Toxicol. 12:293-302, 1974.

Rubin, R., and Chang, J., Effect of the intravenous administration of the solubilized plasticizer, di(2-ethylhexyl)phthalate on the lung and on the survival of transfused rats. Toxicol. Appl. Pharmacol. 45(1):230, 1978.

Sadtler Standard Spectra, Sadtler Research Laboratories, Philadelphia, Pennsylvania, IR No. 28, NMR No. 9392.

Saffiotti, U., Montesano, R., Sellakumar, A. R., Cefis, F., and Kaufman, D. G., Respiratory tract carcinogenesis in hamsters induced by different numbers of administration of benzo(a)pyrene and ferric oxide. Cancer Res. 32:1073-1081, 1972.

Shaffer, C., Carpenter, C., and Smyth, H., Acute and subacute toxicity of di(2-ethylhexyl) phthalate with note upon its metabolism. J. Ind. Hyg. Toxicol. 27(5):130-135, 1945.

Simmon, V., Kauhanen, K., and Tardiff, R., Mutagenic activity of chemicals identified in drinking water. Dev. Toxicol. Environ. Sci. 2:249-258, 1977.

Singh, A., Lawrence, W., and Autian, J. Teratogenicity of phthalate esters in rats. J. Pharm. Sci. 61:51, 1972.

Singh, A., Lawrence, W., and Autian, J., Mutagenic and antifertility sensitivities of mice to di-2-ethylhexyl phthalate (DEHP) and dimethoxyethyl phthalate (DMEP). Toxicol. Appl. Pharmacol. 29:35-46, 1974.

Sontag, J. M., Page, N. P., Saffiotti, U., Guidelines for Carcinogen Bioassay in Small Rodents, DHHS Publication No. (NIH) 76-801, Carcinogenesis Program, National Cancer Institute, Bethesda, MD, 1976.

Tanaka, A., Adachi, T., Takahashi, T., and Yamaha, T., Biochemical studies on phthalic esters: I. Elimination, distribution and metabolism of di-(2-ethylhexyl)phthalate in rats. Toxicology 4:253-264, 1975.



Tarone, R. E., Tests for trend in life table analysis. Biometrika 62:679-682, 1975.

Thomas, J., Darby, T., Wallin, R., Garvin, P., and Martis, J. A review of the biological effects of di-(2-ethylhexyl) phthalate. Toxicol. Appl. Pharmacol. 45:1-27, 1978.

USITC, United States International Trade Commission, Synthetic Organic Chemicals: United States Production and Sales 1977, USITC Publication 920, U.S. Government Printing Office, Washington, D.C., 1978.

Ward, J. M., Goodman, D. G., Griesemer, R. A., Hardisty, J. F., Schueler, R. L., Squire, R. A., and Strandberg, J. D., Quality assurance for pathology in rodent carcinogenesis tests. J. Environ. Path. Toxicol. 2:371-378, 1978.

Yagi, Y., Tutikawa, K., and Shimoi, N., Teratogenicity and mutagenicity of a phthalate ester. Teratology 14:259-260, 1976.

Yamada, A., Toxicity of phthalic acid esters and hepatotoxicity of di-(2-ethyl hexyl) phthalate. Shokuhin Eiseigaku Zasshi 15(3):147-152, 1974.



**APPENDIX A**

**Summary of the Incidence of Neoplasms  
in Rats Fed Diets Containing  
Di(2-ethylhexyl)phthalate**



TABLE A1.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE RATS FED DIETS  
CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
INTEGUMENTARY SYSTEM			
*SKIN	(50)	(50)	(50)
SQUAMOUS CELL PAPILLOMA	1 (2%)		
SQUAMOUS CELL CARCINOMA			2 (4%)
SEBACEOUS ADENOMA	1 (2%)		
KERATOACANTHOMA	1 (2%)		
*SUBCUT TISSUE	(50)	(50)	(50)
SQUAMOUS CELL CARCINOMA			1 (2%)
FIBROMA	1 (2%)	2 (4%)	1 (2%)
FIBROSARCOMA	1 (2%)		1 (2%)
LIPOMA		1 (2%)	
RESPIRATORY SYSTEM			
#LUNG	(50)	(49)	(49)
SQUAMOUS CELL CARCINOMA, METASTA	1 (2%)		
ALVEOLAR/BRONCHIOLAR ADENOMA	1 (2%)	1 (2%)	
ALVEOLAR/BRONCHIOLAR CARCINOMA			1 (2%)
C-CELL CARCINOMA, METASTATIC	1 (2%)		
FIBROSARCOMA, METASTATIC			1 (2%)
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS	(50)	(50)	(50)
MALIG.LYMPHOMA, HISTIOCYTIC TYPE	1 (2%)		
MYELOMONOCYTIC LEUKEMIA	13 (26%)	20 (40%)	17 (34%)
#SALIVARY GLAND	(47)	(46)	(49)
LEUKEMIA, NOS		1 (2%)	
#LIVER	(50)	(49)	(49)
KUPFFER-CELL SARCOMA			1 (2%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
<b>CIRCULATORY SYSTEM</b>			
#SPLEEN	(49)	(48)	(47)
HEMANGIOSARCOMA	1 (2%)		
#HEART/ATRIUM	(50)	(50)	(49)
HEMANGIOSARCOMA	1 (2%)		
<b>DIGESTIVE SYSTEM</b>			
#LIVER	(50)	(49)	(49)
NEOPLASTIC NODULE	2 (4%)	5 (10%)	7 (14%)
HEPATOCELLULAR CARCINOMA	1 (2%)	1 (2%)	5 (10%)
#PANCREAS	(48)	(46)	(46)
ACINAR-CELL ADENOMA			1 (2%)
ACINAR-CELL CARCINOMA		1 (2%)	
#DUODENUM	(48)	(46)	(47)
SARCOMA, NOS			1 (2%)
#JEJUNUM	(48)	(46)	(47)
MUCINOUS ADENOCARCINOMA	1 (2%)		
<b>URINARY SYSTEM</b>			
#URINARY BLADDER	(47)	(45)	(44)
TRANSITIONAL-CELL PAPILLOMA			1 (2%)
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY	(46)	(43)	(49)
CARCINOMA, NOS	4 (9%)	1 (2%)	
ADENOMA, NOS	4 (9%)	5 (12%)	1 (2%)
#ADRENAL	(50)	(49)	(49)
PHEOCHROMOCYTOMA	2 (4%)	2 (4%)	
PHEOCHROMOCYTOMA, MALIGNANT	1 (2%)	1 (2%)	
#THYROID	(48)	(47)	(46)
FOLLICULAR-CELL CARCINOMA	1 (2%)		

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
C-CELL ADENOMA	1 (2%)	1 (2%)	
C-CELL CARCINOMA	4 (8%)	1 (2%)	
#PANCREATIC ISLETS	(48)	(46)	(46)
ISLET-CELL ADENOMA	2 (4%)	1 (2%)	
ISLET-CELL CARCINOMA	1 (2%)	1 (2%)	1 (2%)
<b>REPRODUCTIVE SYSTEM</b>			
*MAMMARY GLAND	(50)	(50)	(50)
FIBROADENOMA		1 (2%)	
*PREPUTIAL GLAND	(50)	(50)	(50)
CARCINOMA, NOS	1 (2%)	2 (4%)	
#TESTIS	(49)	(44)	(48)
INTERSTITIAL-CELL TUMOR	47 (96%)	42 (95%)	11 (23%)
<b>NERVOUS SYSTEM</b>			
#BRAIN	(50)	(50)	(50)
ASTROCYTOMA			1 (2%)
<b>SPECIAL SENSE ORGANS</b>			
*EAR	(50)	(50)	(50)
C-CELL CARCINOMA, METASTATIC	1 (2%)		
*EXTERNAL EAR	(50)	(50)	(50)
SQUAMOUS CELL CARCINOMA	1 (2%)		
FIBROSARCOMA		1 (2%)	
*EAR CANAL	(50)	(50)	(50)
SQUAMOUS CELL CARCINOMA	1 (2%)		
CERUMINOUS CARCINOMA	1 (2%)		
<b>MUSCULOSKELETAL SYSTEM</b>			
NONE			
<b>BODY CAVITIES</b>			
*BODY CAVITIES	(50)	(50)	(50)
MESOTHELIOMA, NOS	1 (2%)		

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**TABLE A1. MALE RATS: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
*TUNICA VAGINALIS MESOTHELIOMA, NOS	(50)	(50) 1 (2%)	(50) 1 (2%)
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS MESOTHELIOMA, NOS	(50)	(50) 1 (2%)	(50)
ANIMAL DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH <sup>a</sup>	12	20	11
MORIBUND SACRIFICE	8	2	6
SCHEDULED SACRIFICE			
ACCIDENTALLY KILLED			
TERMINAL SACRIFICE	30	28	33
ANIMAL MISSING			
<sup>a</sup> INCLUDES AUTOLYZED ANIMALS			
TUMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS*	49	47	38
TOTAL PRIMARY TUMORS	98	93	54
TOTAL ANIMALS WITH BENIGN TUMORS	47	43	15
TOTAL BENIGN TUMORS	61	56	15
TOTAL ANIMALS WITH MALIGNANT TUMORS	30	26	25
TOTAL MALIGNANT TUMORS	34	30	31
TOTAL ANIMALS WITH SECONDARY TUMORS#	2		1
TOTAL SECONDARY TUMORS	3		1
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT	3	7	8
TOTAL UNCERTAIN TUMORS	3	7	8
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			



TABLE A2.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE RATS FED DIETS  
CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
INTEGUMENTARY SYSTEM			
*SUBCUT TISSUE	(50)	(50)	(50)
UNDIFFERENTIATED CARCINOMA	1 (2%)		
SQUAMOUS CELL CARCINOMA		1 (2%)	
RESPIRATORY SYSTEM			
#LUNG	(49)	(50)	(50)
UNDIFFERENTIATED CARCINOMA METAS	1 (2%)		
FIBROSARCOMA, METASTATIC			1 (2%)
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS	(50)	(50)	(50)
MYELOMONOCYTTIC LEUKEMIA	10 (20%)	14 (28%)	17 (34%)
GRANULOCYTTIC LEUKEMIA	1 (2%)		
#MEDIASTINAL L.NODE	(47)	(48)	(46)
UNDIFFERENTIATED CARCINOMA METAS	1 (2%)		
SQUAMOUS CELL CARCINOMA		1 (2%)	
CIRCULATORY SYSTEM			
#UTERUS	(49)	(50)	(50)
HEMANGIOMA		1 (2%)	
DIGESTIVE SYSTEM			
#LIVER	(50)	(49)	(50)
NEOPLASTIC NODULE		4 (8%)	5 (10%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED

**TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
HEPATOCELLULAR CARCINOMA		2 (4%)	8 (16%)
URINARY SYSTEM			
NONE			
ENDOCRINE SYSTEM			
#PITUITARY	(47)	(47)	(48)
CARCINOMA, NOS	4 (9%)	1 (2%)	2 (4%)
ADENOMA, NOS	20 (43%)	12 (26%)	18 (38%)
#ADRENAL	(49)	(48)	(50)
CORTICAL ADENOMA		1 (2%)	2 (4%)
PHEOCHROMOCYTOMA		1 (2%)	
PHEOCHROMOCYTOMA, MALIGNANT	1 (2%)	1 (2%)	
#THYROID	(48)	(49)	(49)
C-CELL ADENOMA		1 (2%)	
C-CELL CARCINOMA	1 (2%)		
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND	(50)	(50)	(50)
CARCINOMA, NOS		1 (2%)	
ADENOCARCINOMA, NOS	1 (2%)		1 (2%)
PAPILLARY CYSTADENOCARCINOMA, NOS	1 (2%)		
FIBROADENOMA	10 (20%)	16 (32%)	3 (6%)
*CLITORAL GLAND	(50)	(50)	(50)
CARCINOMA, NOS	4 (8%)	1 (2%)	1 (2%)
#UTERUS	(49)	(50)	(50)
ADENOCARCINOMA, NOS			1 (2%)
ENDOMETRIAL STROMAL POLYP	7 (14%)	13 (26%)	13 (26%)
#OVARY	(48)	(50)	(49)
GRANULOSA-CELL TUMOR	1 (2%)		
NERVOUS SYSTEM			
#BRAIN	(49)	(50)	(50)
ASTROCYTOMA	2 (4%)		

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
MENINGIOMA	1 (2%)		
SPECIAL SENSE ORGANS			
*EAR	(50)	(50)	(50)
SQUAMOUS CELL CARCINOMA	1 (2%)		
*EXTERNAL EAR	(50)	(50)	(50)
FIBROSARCOMA			2 (4%)
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
*ABDOMINAL CAVITY	(50)	(50)	(50)
SQUAMOUS CELL CARCINOMA, INVASIV		1 (2%)	
SARCOMA, NOS		1 (2%)	1 (2%)
LEIOMYOSARCOMA	1 (2%)		
ALL OTHER SYSTEMS			
NONE			
ANIMAL DISPOSITION SUMMARY			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH <sup>a</sup>	10	10	6
MORIBUND SACRIFICE	4	6	6
SCHEDULED SACRIFICE			
ACCIDENTALLY KILLED			
TERMINAL SACRIFICE	36	34	38
ANIMAL MISSING			
<sup>a</sup> INCLUDES AUTOLYZED ANIMALS			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

**TABLE A2. FEMALE RATS: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
TUMOR SUMMARY			
TOTAL ANIMALS WITH PRIMARY TUMORS*	41	43	49
TOTAL PRIMARY TUMORS	67	72	74
TOTAL ANIMALS WITH BENIGN TUMORS	32	33	31
TOTAL BENIGN TUMORS	38	45	36
TOTAL ANIMALS WITH MALIGNANT TUMORS	24	20	30
TOTAL MALIGNANT TUMORS	28	23	33
TOTAL ANIMALS WITH SECONDARY TUMORS#	1	1	1
TOTAL SECONDARY TUMORS	2	1	1
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT	1	4	5
TOTAL UNCERTAIN TUMORS	1	4	5
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			

APPENDIX B

Summary of the Incidence of Neoplasms  
in Mice Fed Diets Containing  
Di(2-ethylhexyl)phthalate



TABLE B1.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN MALE MICE FED DIETS  
CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	49	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	49	50
INTEGUMENTARY SYSTEM			
*EXTERNAL EAR FIBROUS HISTIOCYTOMA	(50) 1 (2%)	(49)	(50)
*SKIN FIBROMA	(50) 1 (2%)	(49)	(50) 1 (2%)
*SUBCUT TISSUE FIBROMA FIBROSARCOMA LIPOSARCOMA	(50) 1 (2%)  1 (2%)	(49)  3 (6%)	(50)  1 (2%)
RESPIRATORY SYSTEM			
#LUNG HEPATOCELLULAR CARCINOMA, METAST ALVEOLAR/BRONCHIOLAR ADENOMA ALVEOLAR/BRONCHIOLAR CARCINOMA SARCOMA, NOS, METASTATIC LIPOSARCOMA, METASTATIC	(50)  6 (12%) 4 (8%) 1 (2%) 1 (2%)	(49) 7 (14%) 6 (12%) 3 (6%)	(50) 5 (10%) 5 (10%) 2 (4%)
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS MALIGNANT LYMPHOMA, NOS MALIG.LYMPHOMA, HISTIOCYTIC TYPE MALIGNANT LYMPHOMA, MIXED TYPE	(50) 6 (12%)  	(49) 3 (6%) 2 (4%)	(50) 5 (10%)  1 (2%)
#SPLEEN MALIGNANT LYMPHOMA, NOS MALIG.LYMPHOMA, HISTIOCYTIC TYPE	(50) 1 (2%)	(48) 1 (2%)	(49) 1 (2%)
#MESENTERIC L. NODE MALIGNANT LYMPHOMA, NOS	(43) 1 (2%)	(40) 1 (3%)	(42)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED

**TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
MALIG.LYMPHOMA, HISTIOCYTIC TYPE		1 (3%)	
#PEYER'S PATCH MALIGNANT LYMPHOMA, NOS	(44)	(46)	(47) 1 (2%)
<b>CIRCULATORY SYSTEM</b>			
#SPLEEN HEMANGIOSARCOMA	(50)	(48)	(49) 1 (2%)
#HEART SARCOMA, NOS, METASTATIC	(50) 1 (2%)	(48)	(50)
#LIVER HEMANGIOSARCOMA	(50) 1 (2%)	(48)	(50)
#U.BLADDER/SUBMUCOSA HEMANGIOMA	(48)	(47) 1 (2%)	(50)
<b>DIGESTIVE SYSTEM</b>			
#LIVER HEPATOCELLULAR ADENOMA	(50) 6 (12%)	(48) 11 (23%)	(50) 10 (20%)
HEPATOCELLULAR CARCINOMA	9 (18%)	14 (29%)	19 (38%)
SARCOMA, NOS, METASTATIC	1 (2%)		
<b>URINARY SYSTEM</b>			
#KIDNEY ALVEOLAR/BRONCHIOLAR CA, METASTA	(50)	(48) 1 (2%)	(50)
TUBULAR-CELL ADENOMA	1 (2%)		
SARCOMA, NOS, METASTATIC	1 (2%)		
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY ADENOMA, NOS	(34)	(40) 1 (3%)	(36)
#ADRENAL CORTICAL ADENOMA	(48) 1 (2%)	(47)	(48)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED



**TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
<b>REPRODUCTIVE SYSTEM</b>			
*PREPUTIAL GLAND CARCINOMA, NOS	(50)	(49)	(50) 1 (2%)
<b>NERVOUS SYSTEM</b>			
NONE			
<b>SPECIAL SENSE ORGANS</b>			
*HARDERIAN GLAND ADENOMA, NOS	(50) 1 (2%)	(49) 1 (2%)	(50) 2 (4%)
<b>MUSCULOSKELETAL SYSTEM</b>			
*RIB SARCOMA, NOS	(50) 1 (2%)	(49)	(50)
<b>BODY CAVITIES</b>			
NONE			
<b>ALL OTHER SYSTEMS</b>			
NONE			
<b>ANIMAL DISPOSITION SUMMARY</b>			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH <sup>a</sup>	16	9	15
MORIBUND SACRIFICE		2	
SCHEDULED SACRIFICE			
ACCIDENTALLY KILLED			
TERMINAL SACRIFICE	34	38	35
ANIMAL MISSING			
<sup>a</sup> INCLUDES AUTOLYZED ANIMALS			
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

**TABLE B1. MALE MICE: NEOPLASMS (CONTINUED)**

	<b>CONTROL</b>	<b>LOW DOSE</b>	<b>HIGH DOSE</b>
<b>TUMOR SUMMARY</b>			
TOTAL ANIMALS WITH PRIMARY TUMORS*	29	37	38
TOTAL PRIMARY TUMORS	42	48	50
TOTAL ANIMALS WITH BENIGN TUMORS	14	18	14
TOTAL BENIGN TUMORS	18	20	18
TOTAL ANIMALS WITH MALIGNANT TUMORS	21	23	26
TOTAL MALIGNANT TUMORS	24	28	32
TOTAL ANIMALS WITH SECONDARY TUMORS#	2	8	5
TOTAL SECONDARY TUMORS	5	8	5
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT			
TOTAL UNCERTAIN TUMORS			
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			

TABLE B2.

SUMMARY OF THE INCIDENCE OF NEOPLASMS IN FEMALE MICE FED DIETS  
CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
INTEGUMENTARY SYSTEM			
*SUBCUT TISSUE	(50)	(50)	(50)
NEOPLASM, NOS, MALIGNANT	1 (2%)		
SQUAMOUS CELL CARCINOMA		1 (2%)	
SARCOMA, NOS		2 (4%)	
FIBROSARCOMA	1 (2%)		
OSTEOSARCOMA		1 (2%)	
RESPIRATORY SYSTEM			
#LUNG	(50)	(50)	(50)
NEOPLASM, NOS, METASTATIC			1 (2%)
HEPATOCELLULAR CARCINOMA, METAST		1 (2%)	7 (14%)
ALVEOLAR/BRONCHIOLAR ADENOMA			1 (2%)
ALVEOLAR/BRONCHIOLAR CARCINOMA		1 (2%)	1 (2%)
OSTEOSARCOMA, METASTATIC		1 (2%)	
HEMATOPOIETIC SYSTEM			
*MULTIPLE ORGANS	(50)	(50)	(50)
MALIGNANT LYMPHOMA, NOS	10 (20%)	9 (18%)	13 (26%)
MALIG.LYMPHOMA, HISTIOCYTIC TYPE		4 (8%)	1 (2%)
*HEMATOPOIETIC SYSTEM	(50)	(50)	(50)
NEOPLASM, NOS	1 (2%)	1 (2%)	
#SPLEEN	(48)	(48)	(50)
MALIGNANT LYMPHOMA, NOS		2 (4%)	
MALIG.LYMPHOMA, HISTIOCYTIC TYPE		1 (2%)	
#PEYER'S PATCH	(46)	(45)	(44)
MALIGNANT LYMPHOMA, NOS		1 (2%)	

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
MALIG.LYMPHOMA, HISTIOCYTIC TYPE			1 (2%)
#KIDNEY MALIGNANT LYMPHOMA, NOS	(50)	(50) 1 (2%)	(50)
<b>CIRCULATORY SYSTEM</b>			
#SPLEEN HEMANGIOSARCOMA	(48)	(48) 1 (2%)	(50)
#LIVER HEMANGIOMA HEMANGIOSARCOMA HEMANGIOSARCOMA, METASTATIC	(50) 1 (2%)	(50)  1 (2%)	(50)  1 (2%)
#UTERUS HEMANGIOMA	(48) 1 (2%)	(48)	(50)
#OVARY HEMANGIOMA	(48) 1 (2%)	(43) 1 (2%)	(41)
<b>DIGESTIVE SYSTEM</b>			
#LIVER HEPATOCELLULAR ADENOMA HEPATOCELLULAR CARCINOMA OSTEOSARCOMA, METASTATIC	(50) 1 (2%)	(50) 5 (10%) 7 (14%) 1 (2%)	(50) 1 (2%) 17 (34%)
<b>URINARY SYSTEM</b>			
NONE			
<b>ENDOCRINE SYSTEM</b>			
#PITUITARY CARCINOMA, NOS ADENOMA, NOS	(38)  1 (3%)	(35) 1 (3%)	(35) 1 (3%) 1 (3%)
#ADRENAL PHEOCHROMOCYTOMA	(47)	(45) 1 (2%)	(46) 1 (2%)
#THYROID FOLLICULAR-CELL ADENOMA	(44) 1 (2%)	(41)	(45)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND ADENOCARCINOMA, NOS	(50) 2 (4%)	(50) 3 (6%)	(50) 3 (6%)
#UTERUS ADENOCARCINOMA, NOS	(48)	(48) 1 (2%)	(50)
#CERVIX UTERI ADENOCARCINOMA, NOS	(48)	(48) 1 (2%)	(50)
#OVARY PAPILLARY CYSTADENOMA, NOS TUBULAR ADENOMA	(48) 1 (2%)	(43) 1 (2%)	(41)
NERVOUS SYSTEM			
#BRAIN GLIOMA, NOS	(50) 1 (2%)	(49)	(48)
SPECIAL SENSE ORGANS			
*EYE SQUAMOUS CELL PAPILLOMA	(50)	(50) 1 (2%)	(50)
*HARDERIAN GLAND ADENOMA, NOS	(50)	(50) 1 (2%)	(50)
MUSCULOSKELETAL SYSTEM			
*SKULL OSTEOMA	(50) 1 (2%)	(50)	(50)
BODY CAVITIES			
NONE			
ALL OTHER SYSTEMS			
NONE			

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE B2. FEMALE MICE: NEOPLASMS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
<b>ANIMAL DISPOSITION SUMMARY</b>			
ANIMALS INITIALLY IN STUDY	50	50	50
NATURAL DEATH <sup>a</sup>	10	22	16
MORIBUND SACRIFICE	1	3	1
SCHEDULED SACRIFICE			
ACCIDENTALLY KILLED			
TERMINAL SACRIFICE	39	25	33
ANIMAL MISSING			
<sup>a</sup> INCLUDES AUTOLYZED ANIMALS			
<b>TUMOR SUMMARY</b>			
TOTAL ANIMALS WITH PRIMARY TUMORS*	20	35	34
TOTAL PRIMARY TUMORS	24	48	42
TOTAL ANIMALS WITH BENIGN TUMORS	6	10	4
TOTAL BENIGN TUMORS	8	10	4
TOTAL ANIMALS WITH MALIGNANT TUMORS	14	30	32
TOTAL MALIGNANT TUMORS	15	37	38
TOTAL ANIMALS WITH SECONDARY TUMORS#		3	8
TOTAL SECONDARY TUMORS		4	8
TOTAL ANIMALS WITH TUMORS UNCERTAIN- BENIGN OR MALIGNANT	1	1	
TOTAL UNCERTAIN TUMORS	1	1	
TOTAL ANIMALS WITH TUMORS UNCERTAIN- PRIMARY OR METASTATIC			
TOTAL UNCERTAIN TUMORS			
* PRIMARY TUMORS: ALL TUMORS EXCEPT SECONDARY TUMORS			
# SECONDARY TUMORS: METASTATIC TUMORS OR TUMORS INVASIVE INTO AN ADJACENT ORGAN			

APPENDIX C

Summary of the Incidence of Nonneoplastic  
Lesions in Rats Fed Diets Containing  
Di(2-ethylhexyl)phthalate





TABLE C1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE RATS FED  
DIETS CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
INTEGUMENTARY SYSTEM			
*SKIN	(50)	(50)	(50)
INFLAMMATION, CHRONIC	1 (2%)		
HYPERKERATOSIS		1 (2%)	
ACANTHOSIS	1 (2%)	1 (2%)	
RESPIRATORY SYSTEM			
#LUNG	(50)	(49)	(49)
INFLAMMATION, INTERSTITIAL	1 (2%)		2 (4%)
INFLAMMATION, SUPPURATIVE		1 (2%)	
BRONCHOPNEUMONIA, ACUTE		1 (2%)	
FIBROSIS, FOCAL			1 (2%)
HEMATOPOIETIC SYSTEM			
#BONE MARROW	(50)	(50)	(49)
HYPERPLASIA, NOS		1 (2%)	1 (2%)
#SPLEEN	(49)	(48)	(47)
HEMATOMA, NOS			1 (2%)
FIBROSIS	1 (2%)		
NECROSIS, FOCAL		1 (2%)	
LYMPHOID DEPLETION	1 (2%)		
ERYTHROPOIESIS	1 (2%)		
HYPOPLASIA, LYMPHOID			1 (2%)
#MANDIBULAR L. NODE	(42)	(43)	(47)
HYPERPLASIA, PLASMA CELL		1 (2%)	
#PANCREATIC L. NODE	(42)	(43)	(47)
EDEMA, NOS			1 (2%)
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

**TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
NECROSIS, NOS			1 (2%)
#MESENTERIC L. NODE	(42)	(43)	(47)
HEMORRHAGE		1 (2%)	
INFLAMMATION, ACUTE		1 (2%)	
HYPERPLASIA, PLASMA CELL		1 (2%)	
CIRCULATORY SYSTEM			
*MULTIPLE ORGANS	(50)	(50)	(50)
EMBOLISM, NOS		1 (2%)	
#HEART	(50)	(50)	(49)
FIBROSIS, DIFFUSE			1 (2%)
#HEART/ATRIUM	(50)	(50)	(49)
THROMBUS, MURAL	1 (2%)	1 (2%)	3 (6%)
#HEART/VENTRICLE	(50)	(50)	(49)
FIBROSIS		1 (2%)	
#LEFT VENTRICLE	(50)	(50)	(49)
INFLAMMATION, SUPPURATIVE		1 (2%)	
#MYOCARDIUM	(50)	(50)	(49)
INFLAMMATION, CHRONIC		1 (2%)	
INFLAMMATION, CHRONIC FOCAL		1 (2%)	
CALCIFICATION, NOS	1 (2%)		
#CARDIAC VALVE	(50)	(50)	(49)
ENDOCARDITIS, BACTERIAL		1 (2%)	
#GASTRIC SEROSA	(49)	(49)	(48)
PERIVASCULITIS			1 (2%)
DIGESTIVE SYSTEM			
#SALIVARY GLAND	(47)	(46)	(49)
INFLAMMATION, SUPPURATIVE			1 (2%)
#LIVER	(50)	(49)	(49)
INFLAMMATION, CHRONIC			1 (2%)
NECROSIS, FOCAL			1 (2%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
METAMORPHOSIS FATTY	2 (4%)	1 (2%)	2 (4%)
CYTOPLASMIC CHANGE, NOS			1 (2%)
BASOPHILIC CYTO CHANGE	4 (8%)	2 (4%)	1 (2%)
GROUND-GLASS CYTO CHANGE			2 (4%)
CLEAR-CELL CHANGE	4 (8%)	10 (20%)	11 (22%)
HYPERPLASIA, NOS	1 (2%)		
ANGIECTASIS	1 (2%)		
#LIVER/CENTRIOLOBULAR	(50)	(49)	(49)
CONGESTION, NOS		1 (2%)	
NECROSIS, NOS	2 (4%)	3 (6%)	1 (2%)
METAMORPHOSIS FATTY	1 (2%)		
#BILE DUCT	(50)	(49)	(49)
HYPERPLASIA, NOS	31 (62%)	2 (4%)	
HYPERPLASIA, FOCAL		1 (2%)	
#PANCREATIC ACINUS	(48)	(46)	(46)
ATROPHY, FOCAL	1 (2%)		
#GASTRIC MUCOSA	(49)	(49)	(48)
INFLAMMATION, ACUTE FOCAL	1 (2%)		
CALCIFICATION, NOS	1 (2%)		
#FORESTOMACH	(49)	(49)	(48)
ULCER, FOCAL	1 (2%)		
ULCER, ACUTE			2 (4%)
INFLAMMATION, CHRONIC			1 (2%)
HYPERPLASIA, EPITHELIAL			1 (2%)
HYPERPLASIA, BASAL CELL			2 (4%)
#CARDIAC STOMACH	(49)	(49)	(48)
CALCIFICATION, NOS		1 (2%)	
#COLON	(48)	(46)	(44)
NEMATODIASIS	3 (6%)	1 (2%)	3 (7%)
URINARY SYSTEM			
#KIDNEY	(50)	(49)	(49)
PYELONEPHRITIS SUPPURATIVE	1 (2%)		
NEPHROSIS, NOS	49 (98%)	45 (92%)	46 (94%)
CALCINOSIS, NOS	1 (2%)		
HEMOSIDEROSIS		4 (8%)	

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
#RENAL PAPILLA CALCIFICATION, NOS	(50)	(49)	(49) 1 (2%)
#KIDNEY/TUBULE NECROSIS, NOS	(50)	(49) 1 (2%)	(49)
#URINARY BLADDER INFLAMMATION, SUPPURATIVE	(47)	(45)	(44) 1 (2%)
ENDOCRINE SYSTEM			
#PITUITARY	(46)	(43)	(49)
CYST, NOS	1 (2%)	1 (2%)	1 (2%)
HEMORRHAGIC CYST	1 (2%)		1 (2%)
HYPERTROPHY, NOS	1 (2%)		22 (45%)
#ADRENAL	(50)	(49)	(49)
HYPERPLASIA, NOS		1 (2%)	
HYPERPLASIA, FOCAL	1 (2%)		
#ADRENAL MEDULLA	(50)	(49)	(49)
HEMORRHAGE		1 (2%)	
#THYROID	(48)	(47)	(46)
HYPERPLASIA, C-CELL	1 (2%)	1 (2%)	
#PARATHYROID	(16)	(15)	(20)
HYPERPLASIA, NOS		1 (7%)	
#PANCREATIC ISLETS	(48)	(46)	(46)
HYPERPLASIA, NOS	2 (4%)	1 (2%)	
HYPERPLASIA, FOCAL	1 (2%)		
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND	(50)	(50)	(50)
HYPERPLASIA, NOS	1 (2%)		
LACTATION	1 (2%)		
*PREPUTIAL GLAND	(50)	(50)	(50)
INFLAMMATION, SUPPURATIVE		1 (2%)	
INFLAMMATION, ACUTE			1 (2%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
HYPERPLASIA, NOS			1 (2%)
#PROSTATE INFLAMMATION, SUPPURATIVE	(48) 1 (2%)	(44) 1 (2%)	(46) 3 (7%)
#TESTIS HYPERPLASIA, INTERSTITIAL CELL	(49)	(44)	(48) 1 (2%)
#TESTIS/TUBULE DEGENERATION, NOS	(49) 1 (2%)	(44) 2 (5%)	(48) 43 (90%)
NERVOUS SYSTEM			
#CEREBRAL CORTEX HEMORRHAGE	(50)	(50)	(50) 1 (2%)
#CEREBELLUM HEMORRHAGE	(50) 1 (2%)	(50)	(50) 1 (2%)
SPECIAL SENSE ORGANS			
NONE			
MUSCULOSKELETAL SYSTEM			
*SKELETAL MUSCLE INFLAMMATION, SUPPURATIVE	(50)	(50)	(50) 1 (2%)
BODY CAVITIES			
*ABDOMINAL CAVITY NECROSIS, FAT	(50)	(50) 1 (2%)	(50)
*PERITONEUM INFLAMMATION, GRANULOMATOUS	(50)	(50)	(50) 1 (2%)
*MESENTERY STEATITIS NECROSIS, FAT	(50) 2 (4%)	(50) 1 (2%)	(50)
ALL OTHER SYSTEMS			
ADIPOSE TISSUE NECROSIS, FAT	1		1

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED

**TABLE C1. MALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
OMENTUM STEATITIS			1
SPECIAL MORPHOLOGY SUMMARY			
NO LESION REPORTED			1
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE C2.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE RATS FED  
DIETS CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
INTEGUMENTARY SYSTEM			
*SKIN	(50)	(50)	(50)
ULCER, FOCAL			1 (2%)
HYPERKERATOSIS			1 (2%)
RESPIRATORY SYSTEM			
#LUNG/BRONCHIOLE INFLAMMATION, SUPPURATIVE	(49) 1 (2%)	(50)	(50)
#LUNG CONGESTION, ACUTE PASSIVE	(49) 1 (2%)	(50)	(50)
CONGESTION, CHRONIC PASSIVE		1 (2%)	
INFLAMMATION, INTERSTITIAL			1 (2%)
BRONCHOPNEUMONIA, ACUTE	1 (2%)		
HYPERPLASIA, ALVEOLAR EPITHELIUM			1 (2%)
HEMATOPOIETIC SYSTEM			
#SPLEEN	(50)	(50)	(50)
NECROSIS, NOS		1 (2%)	
HEMOSIDEROSIS		2 (4%)	
LYMPHOID DEPLETION		1 (2%)	
HEMATOPOIESIS	1 (2%)	1 (2%)	
ERYTHROPOIESIS		1 (2%)	
HYPOPLASIA, LYMPHOID			1 (2%)
#MEDIASTINAL L. NODE CONGESTION, NOS	(47)	(48) 1 (2%)	(46)
#MESENTERIC L. NODE CONGESTION, NOS	(47)	(48) 1 (2%)	(46)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY

\* NUMBER OF ANIMALS NECROPSIED

**TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
#LIVER HEMATOPOIESIS	(50) 1 (2%)	(49)	(50)
CIRCULATORY SYSTEM			
#MYOCARDIUM INFLAMMATION, ACUTE FOCAL FIBROSIS DEGENERATION, NOS	(49)  1 (2%)	(49) 1 (2%)	(50)  1 (2%)
*MESENTERY THROMBOSIS, NOS PERIARTERITIS	(50) 1 (2%) 1 (2%)	(50)	(50)
DIGESTIVE SYSTEM			
#LIVER INFLAMMATION ACTIVE CHRONIC GRANULOMA, NOS HEPATITIS, TOXIC METAMORPHOSIS FATTY BASOPHILIC CYTO CHANGE FOCAL CELLULAR CHANGE CLEAR-CELL CHANGE ANGIECTASIS	(50)  1 (2%) 4 (8%) 27 (54%) 1 (2%)	(49)  1 (2%) 29 (59%) 3 (6%)	(50) 1 (2%) 1 (2%) 17 (34%) 2 (4%) 3 (6%) 1 (2%)
#LIVER/CENTRIOLOBULAR NECROSIS, NOS	(50) 1 (2%)	(49) 1 (2%)	(50)
#BILE DUCT CYST, NOS HYPERPLASIA, NOS HYPERPLASIA, FOCAL	(50)  6 (12%)	(49)  1 (2%) 1 (2%)	(50) 1 (2%) 1 (2%) 2 (4%)
#PANCREATIC ACINUS ATROPHY, NOS ATROPHY, FOCAL	(47) 1 (2%)	(47)	(49)  1 (2%)
#GASTRIC MUCOSA ULCER, NOS	(49) 1 (2%)	(50)	(50)
#FORESTOMACH INFLAMMATION, NECROTIZING	(49)	(50)	(50) 1 (2%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED



**TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
ULCER, ACUTE	1 (2%)		
#COLON NEMATODIASIS	(49) 4 (8%)	(48) 3 (6%)	(48) 2 (4%)
URINARY SYSTEM			
#KIDNEY NEPHROSIS, NOS HEMOSIDEROSIS	(50) 29 (58%) 1 (2%)	(50) 32 (64%) 4 (8%)	(50) 33 (66%) 6 (12%)
#KIDNEY/CORTEX CYST, NOS	(50) 1 (2%)	(50)	(50)
#RENAL PAPILLA CALCIFICATION, NOS	(50) 1 (2%)	(50)	(50)
#KIDNEY/TUBULE INFECTION, BACTERIAL	(50)	(50) 1 (2%)	(50)
#URINARY BLADDER HYPERPLASIA, EPITHELIAL	(47)	(49)	(47) 1 (2%)
#U. BLADDER/MUCOSA HYPERPLASIA, FOCAL HYPERPLASIA, DIFFUSE	(47)	(49)	(47) 1 (2%) 1 (2%)
#U. BLADDER/SUBMUCOSA HEMORRHAGE	(47) 1 (2%)	(49)	(47)
#U. BLADDER/SEROSA INFLAMMATION, ACUTE/CHRONIC NECROSIS, NOS	(47)	(49)	(47) 1 (2%) 1 (2%)
ENDOCRINE SYSTEM			
#PITUITARY CYST, NOS MULTIPLE CYSTS HEMORRHAGIC CYST HEMOSIDEROSIS	(47) 1 (2%) 10 (21%) 1 (2%) 1 (2%)	(47)  10 (21%) 1 (2%) 1 (2%)	(48) 4 (8%) 5 (10%) 1 (2%)
#ADRENAL METAMORPHOSIS FATTY	(49) 1 (2%)	(48)	(50) 2 (4%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
HYPERPLASIA, NOS	1 (2%)		
#ADRENAL CORTEX HYPERPLASIA, FOCAL	(49)	(48)	(50) 1 (2%)
#ADRENAL MEDULLA HYPERPLASIA, FOCAL	(49) 1 (2%)	(48)	(50)
#THYROID CYSTIC FOLLICLES HYPERPLASIA, C-CELL	(48) 1 (2%)	(49) 1 (2%) 1 (2%)	(49) 1 (2%) 2 (4%)
#THYROID FOLLICLE HYPERPLASIA, CYSTIC	(48) 1 (2%)	(49)	(49)
#PANCREATIC ISLETS HYPERPLASIA, FOCAL	(47) 1 (2%)	(47)	(49)
REPRODUCTIVE SYSTEM			
*MAMMARY GLAND DILATATION/DUCTS HYPERPLASIA, CYSTIC	(50) 2 (4%) 1 (2%)	(50)	(50)
*PREPUTIAL GLAND ABSCESS, NOS	(50)	(50) 1 (2%)	(50)
#UTERUS HYDROMETRA NECROSIS, NOS NECROSIS, HEMORRHAGIC	(49) 1 (2%)	(50) 1 (2%) 1 (2%)	(50)
#UTERUS/ENDOMETRIUM INFLAMMATION, SUPPURATIVE HYPERPLASIA, CYSTIC	(49)	(50) 3 (6%)	(50) 1 (2%)
#OVARY FOLLICULAR CYST, NOS CORPUS LUTEUM CYST	(48)	(50)	(49) 2 (4%) 1 (2%)
NERVOUS SYSTEM			
#PONS HEMORRHAGE	(49)	(50) 2 (4%)	(50)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED

**TABLE C2. FEMALE RATS: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
#CEREBELLUM HEMORRHAGE	(49)	(50)	(50) 1 (2%)
SPECIAL SENSE ORGANS			
*EXTERNAL EAR ACANTHOSIS	(50)	(50)	(50) 1 (2%)
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
*ABDOMINAL CAVITY NECROSIS, FAT	(50)	(50) 1 (2%)	(50) 2 (4%)
*MESENTERY STEATITIS	(50)	(50) 1 (2%)	(50) 2 (4%)
ALL OTHER SYSTEMS			
ADIPOSE TISSUE STEATITIS NECROSIS, FAT		1 1	
SPECIAL MORPHOLOGY SUMMARY			
AUTO/NECROPSY/HISTO PERF	1		
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			



**APPENDIX D**

**Summary of the Incidence of Nonneoplastic  
Lesions in Mice Fed Diets Containing  
Di(2-ethylhexyl)phthalate**



TABLE D1.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN MALE MICE FED  
DIETS CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	49	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	49	50
INTEGUMENTARY SYSTEM			
*SKIN	(50)	(49)	(50)
ULCER, NOS	1 (2%)		
INFLAMMATION, ACUTE			1 (2%)
INFLAMMATION, ACUTE/CHRONIC		1 (2%)	
ACANTHOSIS	1 (2%)		
*SUBCUT TISSUE	(50)	(49)	(50)
EDEMA, NOS	1 (2%)		
STEATITIS	1 (2%)		
ABSCESS, NOS	2 (4%)	1 (2%)	1 (2%)
RESPIRATORY SYSTEM			
#LUNG	(50)	(49)	(50)
HEMORRHAGE	1 (2%)		
HEMATOPOIETIC SYSTEM			
#BONE MARROW	(47)	(48)	(48)
HYPERPLASIA, HEMATOPOIETIC	1 (2%)	2 (4%)	
HEMATOPOIESIS		1 (2%)	
#SPLEEN	(50)	(48)	(49)
CONGESTION, NOS			1 (2%)
ANGIECTASIS			1 (2%)
HYPERPLASIA, LYMPHOID			1 (2%)
HEMATOPOIESIS	1 (2%)	1 (2%)	2 (4%)
#LYMPH NODE	(43)	(40)	(42)
HYPERPLASIA, LYMPHOID	1 (2%)		
#MEDIASTINAL L.NODE	(43)	(40)	(42)
HYPERPLASIA, LYMPHOID	1 (2%)		

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED

**TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
#PANCREATIC L.NODE CONGESTION, NOS	(43) 2 (5%)	(40)	(42)
#AORTIC LYMPH NODE HYPERPLASIA, LYMPHOID	(43)	(40)	(42) 1 (2%)
#LUMBAR LYMPH NODE INFLAMMATION, CHRONIC	(43)	(40) 1 (3%)	(42)
#MESENTERIC L. NODE CONGESTION, NOS	(43) 3 (7%)	(40) 2 (5%)	(42) 3 (7%)
HEMORRHAGE		1 (3%)	
INFLAMMATION, GRANULOMATOUS		1 (3%)	
HYPERPLASIA, NOS	1 (2%)		
HYPERPLASIA, PLASMA CELL		1 (3%)	
HYPERPLASIA, LYMPHOID	5 (12%)	1 (3%)	1 (2%)
HEMATOPOIESIS			1 (2%)
#PEYER'S PATCH HYPERPLASIA, LYMPHOID	(44) 1 (2%)	(46) 1 (2%)	(47)
<b>CIRCULATORY SYSTEM</b>			
*MULTIPLE ORGANS PERIARTERITIS	(50)	(49)	(50) 1 (2%)
#RIGHT VENTRICLE THROMBUS, MURAL	(50)	(48)	(50) 1 (2%)
#MYOCARDIUM INFLAMMATION, ACUTE FOCAL	(50)	(48) 1 (2%)	(50)
INFLAMMATION, CHRONIC	1 (2%)		
#CARDIAC VALVE INFLAMMATION, ACUTE FOCAL	(50)	(48) 1 (2%)	(50)
<b>DIGESTIVE SYSTEM</b>			
#LIVER CYST, NOS	(50)	(48) 1 (2%)	(50)
NECROSIS, FOCAL	1 (2%)		
AMYLOIDOSIS	1 (2%)		

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED



**TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
METAMORPHOSIS FATTY	1 (2%)		1 (2%)
MEGALOCYTOSIS	1 (2%)		
ANGIECTASIS		1 (2%)	
#HEPATIC CAPSULE	(50)	(48)	(50)
INFLAMMATION, CHRONIC FOCAL	1 (2%)		
#BILE DUCT	(50)	(48)	(50)
CYST, NOS	1 (2%)	2 (4%)	3 (6%)
CYSTIC DUCTS		1 (2%)	
INFLAMMATION, CHRONIC	1 (2%)		
HYPERPLASIA, NOS	1 (2%)		
HYPERPLASIA, FOCAL	1 (2%)		
#PANCREAS	(47)	(46)	(46)
CYSTIC DUCTS		1 (2%)	
NECROSIS, FOCAL		1 (2%)	
ATROPHY, NOS	1 (2%)		
#PANCREATIC ACINUS	(47)	(46)	(46)
ATROPHY, FOCAL	1 (2%)		
#GASTRIC MUCOSA	(48)	(47)	(50)
INFLAMMATION, ACUTE FOCAL		1 (2%)	
NECROSIS, FOCAL		1 (2%)	
#FORESTOMACH	(48)	(47)	(50)
INFLAMMATION, CHRONIC	1 (2%)		
HYPERPLASIA, FOCAL		2 (4%)	
#GASTRIC FUNDUS	(48)	(47)	(50)
HYPERPLASIA, FOCAL			1 (2%)
HYPERKERATOSIS			1 (2%)
#SMALL INTESTINE	(44)	(46)	(47)
HYPERPLASIA, ADENOMATOUS	1 (2%)		
<b>URINARY SYSTEM</b>			
#KIDNEY	(50)	(48)	(50)
HYDRONEPHROSIS	1 (2%)		1 (2%)
INFLAMMATION, NOS			1 (2%)
PYELONEPHRITIS SUPPURATIVE			1 (2%)
PYELONEPHRITIS, ACUTE	1 (2%)		
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

**TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
INFLAMMATION, ACUTE FOCAL PYELONEPHRITIS, ACUTE/CHRONIC	1 (2%)	2 (4%)	
INFLAMMATION, CHRONIC	1 (2%)	2 (4%)	10 (20%)
GLOMERULOSCLEROSIS, NOS	2 (4%)		
AMYLOIDOSIS	2 (4%)		
#URINARY BLADDER	(48)	(47)	(50)
INFLAMMATION, NOS			1 (2%)
INFLAMMATION, ACUTE	1 (2%)		
ULCER, ACUTE		1 (2%)	
INFLAMMATION ACUTE AND CHRONIC	1 (2%)		
INFLAMMATION, CHRONIC	1 (2%)		
<b>ENDOCRINE SYSTEM</b>			
#THYROID	(48)	(47)	(47)
FOLLICULAR CYST, NOS			1 (2%)
INFLAMMATION, CHRONIC FOCAL	1 (2%)		
HYPERPLASIA, FOLLICULAR-CELL		1 (2%)	
<b>REPRODUCTIVE SYSTEM</b>			
*PENIS	(50)	(49)	(50)
ULCER, NOS	1 (2%)	1 (2%)	
*PREPUTIAL GLAND	(50)	(49)	(50)
CYSTIC DUCTS	1 (2%)	1 (2%)	
INFLAMMATION, SUPPURATIVE		1 (2%)	1 (2%)
ABSCESS, NOS	1 (2%)		
INFLAMMATION, CHRONIC	1 (2%)		
#PROSTATE	(47)	(43)	(46)
INFLAMMATION, ACUTE	2 (4%)		
#TESTIS/TUBULE	(49)	(48)	(49)
DEGENERATION, NOS	1 (2%)	2 (4%)	7 (14%)
<b>NERVOUS SYSTEM</b>			
NONE			
<b>SPECIAL SENSE ORGANS</b>			
NONE			

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE D1. MALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
MUSCULOSKELETAL SYSTEM			
NONE			
BODY CAVITIES			
*ABDOMINAL CAVITY NECROSIS, FAT	(50) 1 (2%)	(49)	(50)
*MESENTERY STEATITIS	(50) 1 (2%)	(49)	(50)
ALL OTHER SYSTEMS			
*MULTIPLE ORGANS INFLAMMATION, ACUTE	(50)	(49) 1 (2%)	(50)
OMENTUM NECROSIS, FAT			1
SPECIAL MORPHOLOGY SUMMARY			
NO LESION REPORTED	6	4	4
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			

TABLE D2.

SUMMARY OF THE INCIDENCE OF NONNEOPLASTIC LESIONS IN FEMALE MICE FED  
DIETS CONTAINING DI(2-ETHYLHEXYL)PHTHALATE

	CONTROL	LOW DOSE	HIGH DOSE
ANIMALS INITIALLY IN STUDY	50	50	50
ANIMALS NECROPSIED	50	50	50
ANIMALS EXAMINED HISTOPATHOLOGICALLY	50	50	50
INTEGUMENTARY SYSTEM			
*SKIN INFECTION, FUNGAL	(50)	(50)	(50) 1 (2%)
*SUBCUT TISSUE ABSCESS, NOS	(50)	(50)	(50) 1 (2%)
RESPIRATORY SYSTEM			
#LUNG/BRONCHIOLE INFLAMMATION, SUPPURATIVE	(50)	(50)	(50) 1 (2%)
#LUNG INFLAMMATION, INTERSTITIAL	(50)	(50) 1 (2%)	(50)
HEMATOPOIETIC SYSTEM			
#BONE MARROW LEUKEMOID REACTION	(49) 1 (2%)	(48)	(48)
#SPLEEN HYPERPLASIA, LYMPHOID HEMATOPOIESIS	(48)	(48) 2 (4%) 2 (4%)	(50) 2 (4%) 2 (4%)
#LYMPH NODE HYPERPLASIA, NOS	(42)	(39) 1 (3%)	(40)
#MEDIASTINAL L.NODE INFLAMMATION ACUTE PUSTULAR HYPERPLASIA, PLASMA CELL	(42) 1 (2%)	(39) 1 (3%)	(40) 1 (3%)
#MESENTERIC L. NODE CYST, NOS	(42) 1 (2%)	(39)	(40)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
\* NUMBER OF ANIMALS NECROPSIED

**TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
#LUNG	(50)	(50)	(50)
LEUKEMOID REACTION	1 (2%)		
HYPERPLASIA, RETICULUM CELL		1 (2%)	
#LIVER	(50)	(50)	(50)
LEUKOCYTOSIS, NOS	1 (2%)		
HEMATOPOIESIS		1 (2%)	1 (2%)
CIRCULATORY SYSTEM			
#MYOCARDIUM	(50)	(49)	(48)
INFLAMMATION, ACUTE		1 (2%)	
*UTERINE ARTERY	(50)	(50)	(50)
NECROSIS, FIBRINOID	1 (2%)		
DIGESTIVE SYSTEM			
#LIVER	(50)	(50)	(50)
INFLAMMATION, FOCAL			1 (2%)
INFLAMMATION, CHRONIC FOCAL			1 (2%)
FIBROSIS		1 (2%)	
NECROSIS, NOS		2 (4%)	
NECROSIS, FOCAL			2 (4%)
METAMORPHOSIS FATTY	3 (6%)		1 (2%)
BASOPHILIC CYTO CHANGE		1 (2%)	
HEPATOCTOMEGALY	1 (2%)		
ANGIECTASIS		2 (4%)	
#BILE DUCT	(50)	(50)	(50)
CYST, NOS		1 (2%)	
#PANCREAS	(46)	(46)	(45)
DILATATION/DUCTS	1 (2%)	1 (2%)	
CYSTIC DUCTS	3 (7%)	2 (4%)	
ABSCESS, NOS			1 (2%)
INFLAMMATION, CHRONIC		1 (2%)	
ATROPHY, NOS	1 (2%)		
#PANCREATIC ACINUS	(46)	(46)	(45)
ATROPHY, NOS		1 (2%)	
ATROPHY, FOCAL		1 (2%)	

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
#PEYER'S PATCH HYPERPLASIA, NOS	(46)	(45)	(44) 1 (2%)
#COLON NEMATODIASIS	(38)	(44)	(38) 1 (3%)
URINARY SYSTEM			
#KIDNEY MINERALIZATION	(50)	(50) 1 (2%)	(50)
INFLAMMATION, INTERSTITIAL			2 (4%)
INFLAMMATION, CHRONIC	5 (10%)	3 (6%)	3 (6%)
GLOMERULONEPHRITIS, CHRONIC	1 (2%)		
AMYLOIDOSIS	1 (2%)		
#KIDNEY/CORTEX SCAR	(50) 1 (2%)	(50)	(50)
#KIDNEY/TUBULE CYST, NOS	(50)	(50) 1 (2%)	(50)
ENDOCRINE SYSTEM			
#ADRENAL HYPERPLASIA, NODULAR	(47)	(45)	(46) 1 (2%)
#THYROID CYSTIC FOLLICLES	(44)	(41)	(45) 1 (2%)
INFLAMMATION, ACUTE FOCAL	1 (2%)		
HYPERPLASIA, FOLLICULAR-CELL		1 (2%)	1 (2%)
REPRODUCTIVE SYSTEM			
#UTERUS HYDROMETRA	(48) 1 (2%)	(48)	(50) 1 (2%)
HEMATOMA, NOS	1 (2%)		
INFLAMMATION, SUPPURATIVE	1 (2%)		
ATROPHY, NOS			1 (2%)
#UTERUS/ENDOMETRIUM INFLAMMATION, SUPPURATIVE	(48)	(48) 2 (4%)	(50) 6 (12%)

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	CONTROL	LOW DOSE	HIGH DOSE
HYPERPLASIA, CYSTIC	29 (60%)	28 (58%)	22 (44%)
#ENDOMETRIAL GLAND CYST, NOS	(48)	(48)	(50) 1 (2%)
#OVARY/PAROVARIAN INFLAMMATION, NOS INFLAMMATION, CHRONIC	(48) 1 (2%)	(43)	(41) 1 (2%)
#OVARY	(48)	(43)	(41)
CYST, NOS	4 (8%)	3 (7%)	5 (12%)
FOLLICULAR CYST, NOS	3 (6%)		2 (5%)
HEMATOMA, NOS	1 (2%)	1 (2%)	
HEMORRHAGIC CYST		1 (2%)	
INFLAMMATION, SUPPURATIVE	1 (2%)		1 (2%)
ABSCESS, NOS		1 (2%)	
AMYLOIDOSIS	1 (2%)		
EOSINOPHILIC GRANULOMA	1 (2%)		
<b>NERVOUS SYSTEM</b>			
NONE			
<b>SPECIAL SENSE ORGANS</b>			
NONE			
<b>MUSCULOSKELETAL SYSTEM</b>			
NONE			
<b>BODY CAVITIES</b>			
*ABDOMINAL CAVITY	(50)	(50)	(50)
STEATITIS	1 (2%)		
ABSCESS, NOS	1 (2%)		
<b>ALL OTHER SYSTEMS</b>			
NONE			

# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY  
 \* NUMBER OF ANIMALS NECROPSIED

**TABLE D2. FEMALE MICE: NONNEOPLASTIC LESIONS (CONTINUED)**

	<b>CONTROL</b>	<b>LOW DOSE</b>	<b>HIGH DOSE</b>
<b>SPECIAL MORPHOLOGY SUMMARY</b>			
NO LESION REPORTED	5	3	
# NUMBER OF ANIMALS WITH TISSUE EXAMINED MICROSCOPICALLY			
* NUMBER OF ANIMALS NECROPSIED			



**APPENDIX E**

**Analysis of Di(2-ethylhexyl)phthalate  
Midwest Research Institute**



APPENDIX E

Analysis of Di(2-ethylhexyl)phthalate

Midwest Research Institute

A. ELEMENTAL ANALYSIS

Element	C	H
Theory	73.80	9.81
Determined	73.77	9.78
	73.89	9.87

B. BOILING POINT

<u>Determined</u>	<u>Literature Values</u>
b.p. 375° to 392°C (corr.) at 744 torr (Dupont 900 DTA)	No literature b.p. found at atmospheric pressure. Decomposition found to occur at 235°C and 20 mm Hg (Korosy, 1966).

C. DENSITY

<u>Determined</u>	<u>Literature Values</u>
$d_4^{24.5} 0.9765 \pm 0.00055$	$d_4^{20} 0.9843$ (Reith and Eckhardt, 1962)

D. REFRACTIVE INDEX

<u>Determined</u>	<u>Literature Values</u>
$n_D^{20} 1.4854$ $n_D^{25} 1.4845$	$n_D^{20} 1.4868$ (Reith and Eckhardt, 1962)

E. THIN-LAYER CHROMATOGRAPHY

Plates: Silica gel 60 F254

Ref. Standard: Dimethyl  
terephthalate

Amount spotted: 100 and  
300  $\mu$ g

Visualization: Ultraviolet,  
(254 nm); zinc chloride plus  
20% resorcinol in ethanol,  
heat, and 4N sulfuric acid,  
and then heat and 40% aqueous  
potassium hydroxide

System 1: Benzene, 100%

R<sub>f</sub>: 0.45

R<sub>st</sub>: 2.0

System 2: Ethyl acetate, 100%

R<sub>f</sub>: 0.92

R<sub>st</sub>: 1.0

F. VAPOR-PHASE CHROMATOGRAPHY

Instrument: Tracor MT 220  
Detection: Flame ionization  
Inlet temperature: 200°C  
Detector temperature: 260°C

System 1:

Column: 3% OV-1 on 80/100 Supelcoport, 1.8 m x 4 mm I.D.,  
glass

Oven temperature program: 150° to 250°C at 10°C/min

Results: Major peak and two impurities

<u>Peak</u>	<u>Retention Time (min)</u>	<u>Relative Retention Time</u>	<u>Relative Area</u>
1	3.0	0.34	0.2
2	7.2	0.84	0.2
3	8.7	1.00	100.0

System 2:

Column: 3% OV-225 on 80/100 Chromosorb W (HP),  
1.8 m x 4 mm I.D., glass

Oven temperature program: 150° to 250°C at 10°C/min

Results: Major peak and two impurities

<u>Peak</u>	<u>Retention Time (min)</u>	<u>Relative Retention Time</u>	<u>Relative Area</u>
1	2.2	0.30	0.07
2	7.1	0.96	0.20
3	7.4	1.00	100.00

## G. SPECTRAL DATA

### 1. Infrared

Instrument: Beckman IR-12

Cell: Neat, thin film on  
sodium chloride  
plates

Results: See Figure 7

Consistent with literature  
spectrum (Sadtler  
Standard Spectra).

### 2. Ultraviolet/Visible

Instrument: Cary 118

No literature values  
found.

<u><math>\lambda</math> max (nm)</u>	<u><math>\epsilon \times 10^{-3}</math></u>
226	8.7+0.4 ( $\delta$ )
247	1.29+0.004 ( $\delta$ )
281 shoulder	1.171+0.002 ( $\delta$ )

No absorbance between 350 and 800 nm  
(visible range) at a concentration of  
0.2 mg/ml.

Solvent: 95% ethanol

### 3. Nuclear Magnetic Resonance

Instrument: Varian HA-100

Solvent: Chloroform-d with  
internal tetramethylsilane

Assignments: (See Figure 8)

- (a) m,  $\delta$  0.62-1.13 ppm
- (b) m,  $\delta$  1.13-1.88 ppm
- (c) d,  $\delta$  4.25 ppm,  $J_{bc} = 6\text{Hz}$
- (d) m,  $\delta$  7.55 ppm
- (e) m,  $\delta$  7.77 ppm

Basically consistent  
with literature spec-  
trum (Sadtler Standard  
Spectra). Integration  
for aromatic protons  
slightly high.

Integration ratios:

- (a) 11.6
- (b) 17.4
- (c) 4.0
- (d) 2.52
- (e) 2.52




Figure 7. Infrared Absorption Spectrum of Di(2-ethylhexyl)phthalate




Figure 8. Nuclear Magnetic Resonance Spectrum of Di(2-ethylhexyl)phthalate





**APPENDIX F**

**Stability Analysis of Di(2-ethylhexyl)phthalate  
Midwest Research Institute**



## APPENDIX F

### Stability Analysis of Di(2-ethylhexyl)phthalate

Midwest Research Institute

#### HEAT STABILITY

1. MIXING AND STORAGE: Di(2-ethylhexyl)phthalate (2.41657 g) and Wayne Lab Blox<sup>®</sup>Rodent Feed (22.49301 g) were mixed in a mortar. Samples of the mixture were then removed and stored for 2 weeks at -20°, 5°, 25°, and 45°C, respectively.

2. EXTRACTION AND ANALYSIS: One-gram samples of each of the above stability mixtures were triturated twice with 50-ml portions of methanol. The supernatant solutions were combined and diluted to a volume of 100 ml and analyzed by vapor-phase chromatography using the following system.

Instrument: Bendix 2500  
Column: 3% OV-17 on 80/100 Supelcoport, 1.8 m x 4 mm I.D.,  
          glass  
Detection: Flame ionization  
Oven temperature: 250°C, isothermal  
Inlet temperature: 240°C  
Detector temperature: 280°C  
Retention time: 3.79 min

#### 3. RESULTS

<u>Sample (°C)</u>	<u>Average % Compound Recovered</u> <sup>(a)</sup>
-20	9.7 $\pm$ 0.1
5	9.7 $\pm$ 0.1
25	9.9 $\pm$ 0.1
45	9.7 $\pm$ 0.1

---

(a) Corrected for a spike recovery value of 100 $\pm$ 3%.  
Theoretical expected value, 9.7%.

There is no significant difference between the samples stored at the various temperatures.

4. CONCLUSION: Di(2-ethylhexyl)phthalate mixed with feed is stable for 2 weeks at temperatures of up to 45°C.



**APPENDIX G**

**Analysis of Formulated Diets for  
Concentrations of Di(2-ethylhexyl)phthalate**



Appendix G

Analysis of Formulated Diets for  
Concentrations of Di(2-ethylhexyl)phthalate

Mason Research Institute

Samples of 2 g each were extracted with 50 ml methanol. The supernatant solutions were analyzed by vapor-phase chromatography on a 3% OV-17 glass column at 240°C, isothermal.

---

Theoretical Concentration (ppm)	Number of Samples	Sample Analytical Mean (ppm)	Coefficient of Variation (%)	Range (ppm)
3,000	11	2,836	3.6	2,700-3,000
6,000	12	5,850	4.0	5,500-6,200
12,000	11	11,881	5.2	10,800-12,700

---





**NIH Publication No. 82-1773**  
**March 1982**